Test,O
sensitivity,O
is,O
secondary,O
to,O
frequency,O
and,O
turnaround,O
time,O
for,O
COVID,O
‐,O
19,NUMBER
surveillance,O
Daniel,PERSON
B.,PERSON
Larremore1,PERSON
.2,O
.,O
Bryan,PERSON
Wilder3,PERSON
.,O
Evan,PERSON
Lester6,PERSON
.5,O
.,O
Soraya,PERSON
Shehata4,O
.5,O
.,O
James,PERSON
M.,PERSON
Burke6,PERSON
.,O
James,PERSON
A.,PERSON
Hay7,O
.8,O
.,O
Milind,PERSON
Tambe3,PERSON
.,O
Michael,PERSON
J.,PERSON
Mina7,O
.8.9,O
.,O
*,O
.,O
and,O
Roy,PERSON
Park,PERSON
‐,O
er4,O
.6.10.2,O
.,O
*,O
Public,O
Health,O
The,O
COVID,O
‐,O
19,NUMBER
pandemic,O
has,O
created,O
a,O
public,O
health,O
crisis,O
.,O
Because,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
can,O
spread,O
from,O
individ,O
‐,O
uals,O
with,O
pre,O
‐,O
symptomatic,O
.,O
symptomatic,O
.,O
and,O
asymptomatic,O
infec,O
‐,O
tions,O
[,O
1,NUMBER
.,O
2,NUMBER
.,O
3,NUMBER
],O
.,O
the,O
re,O
‐,O
opening,O
of,O
societies,O
and,O
the,O
control,O
of,O
virus,O
spread,O
will,O
be,O
facilitated,O
by,O
robust,O
surveillance,O
.,O
for,O
which,O
virus,O
testing,O
will,O
often,O
be,O
central,O
.,O
After,O
infection,CAUSE_OF_DEATH
.,O
indi,O
‐,O
viduals,O
undergo,O
a,O
period,O
of,O
incubation,O
during,O
which,O
viral,O
titers,O
are,O
usually,O
too,O
low,O
to,O
detect,O
.,O
followed,O
by,O
an,O
exponential,O
growth,O
of,O
virus,O
.,O
leading,O
to,O
a,O
peak,O
viral,O
load,O
and,O
infectiousness,O
.,O
and,O
ending,O
with,O
declining,O
viral,O
levels,O
and,O
clearance,O
[,O
4,NUMBER
],O
.,O
Given,O
the,O
pattern,O
of,O
viral,O
load,O
kinetics,O
[,O
4,NUMBER
],O
.,O
we,O
model,O
surveillance,O
effec,O
‐,O
tiveness,O
considering,O
test,O
sensitivities,O
.,O
frequency,O
.,O
and,O
sample,O
‐,O
to,O
‐,O
answer,O
reporting,O
time,O
.,O
These,O
results,O
demonstrate,O
that,O
effec,O
‐,O
tive,O
surveillance,O
.,O
including,O
time,O
to,O
first,ORDINAL
detection,O
and,O
outbreak,O
control,O
.,O
depends,O
largely,O
on,O
frequency,O
of,O
testing,O
and,O
the,O
speed,O
of,O
reporting,O
.,O
and,O
is,O
only,O
marginally,O
improved,O
by,O
high,O
test,O
sensitiv,O
‐,O
ity,O
.,O
We,O
therefore,O
conclude,O
that,O
surveillance,O
should,O
prioritize,O
accessibility,O
.,O
frequency,O
.,O
and,O
sample,O
‐,O
to,O
‐,O
answer,O
time,O
;,O
analytical,O
limits,O
of,O
detection,O
should,O
be,O
secondary,O
.,O
The,O
reliance,O
on,O
testing,O
as,O
a,O
means,O
to,O
safely,O
reopen,O
societies,O
has,O
placed,O
a,O
microscope,O
on,O
the,O
analytical,O
sensitivity,O
of,O
virus,O
assays,O
.,O
with,O
a,O
gold,O
‐,O
standard,O
of,O
quantitative,O
real,O
‐,O
time,O
polymerase,O
chain,O
reaction,O
(,O
qPCR,O
),O
.,O
These,O
assays,O
have,O
analytical,O
limits,O
of,O
detection,O
that,O
are,O
usually,O
with,O
‐,O
in,O
around,O
103,NUMBER
viral,O
RNA,O
copies,O
per,O
ml,O
(,O
cp,O
/,O
ml,O
),O
[,O
5,NUMBER
],O
.,O
However,O
.,O
qPCR,O
remains,O
expensive,O
and,O
as,O
a,O
laboratory,O
based,O
assay,O
often,O
have,O
sam,O
‐,O
ple,O
‐,O
to,O
‐,O
result,O
times,O
of,O
24,NUMBER
‐,O
48,DURATION
hours,DURATION
.,O
New,O
developments,O
in,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
diagnostics,O
have,O
the,O
potential,O
to,O
reduce,O
cost,O
significant,O
‐,O
ly,O
.,O
allowing,O
for,O
expanded,O
testing,O
or,O
greater,O
frequency,O
of,O
testing,O
and,O
can,O
reduce,O
turnaround,O
time,O
to,O
minutes,DURATION
.,O
These,O
assays,O
however,O
largely,O
do,O
not,O
meet,O
the,O
gold,O
standard,O
for,O
analytical,O
sensitivity,O
.,O
which,O
has,O
encumbered,O
translation,O
of,O
these,O
assays,O
for,O
widescale,O
use,O
[,O
6,NUMBER
],O
.,O
Three,NUMBER
features,O
of,O
the,O
viral,O
increase,O
.,O
infectivity,O
.,O
and,O
decline,O
during,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
led,O
us,O
to,O
hypothesize,O
that,O
there,O
might,O
be,O
minimal,O
differences,O
in,O
effective,O
surveillance,O
us,O
‐,O
ing,O
viral,O
detection,O
tests,O
of,O
different,O
sensitivities,O
.,O
such,O
as,O
RT,O
‐,O
qPCR,O
with,O
a,O
limit,O
of,O
detection,O
(,O
LOD,O
),O
at,O
103,NUMBER
cp,O
/,O
ml,O
[,O
5,NUMBER
],O
compared,O
to,O
often,O
cheaper,O
or,O
faster,O
assays,O
with,O
higher,O
limits,O
of,O
detection,O
(,O
i.e.,O
.,O
around,O
105,NUMBER
cp,O
/,O
ml,O
),O
samples,O
collected,O
from,O
patients,O
display,O
‐,O
ing,O
less,O
than,O
106,NUMBER
N,O
or,O
E,O
RNA,O
cp,O
/,O
ml,O
contain,O
minimal,O
or,O
no,O
measur,O
‐,O
able,O
infectious,O
virus,O
[,O
7,NUMBER
.,O
8,NUMBER
.,O
9,NUMBER
],O
.,O
either,O
class,O
of,O
test,O
should,O
de,O
‐,O
tect,O
individuals,O
who,O
are,O
is,O
likely,O
due,O
to,O
(,O
i,O
),O
the,O
fact,O
that,O
the,O
N,O
and,O
E,O
RNAs,O
are,O
also,O
present,DATE
in,O
abundant,O
subgenomic,O
mRNAs,O
.,O
leading,O
to,O
overestimation,O
of,O
the,O
number,O
of,O
actual,O
viral,O
genomes,O
by,O
100,NUMBER
‐,O
1000X,O
[,O
10,NUMBER
],O
.,O
(,O
ii,O
),O
technical,O
artifacts,O
of,O
RT,O
‐,O
PCR,O
at,O
Ct,O
values,O
>,O
35,NUMBER
due,O
to,O
limited,O
template,O
[,O
11,NUMBER
.,O
12,NUMBER
],O
.,O
and,O
(,O
iii,O
),O
the,O
production,O
of,O
during,O
the,O
exponential,O
growth,O
of,O
the,O
virus,O
.,O
the,O
time,O
difference,O
between,O
103,NUMBER
and,NUMBER
105,NUMBER
cp,O
/,O
ml,O
is,O
short,O
.,O
allowing,O
only,O
a,O
limited,O
win,O
‐,O
dow,O
in,O
which,O
only,O
the,O
more,O
sensitive,O
test,O
could,O
diagnose,O
individ,O
‐,O
uals,O
.,O
For,O
qPCR,O
.,O
this,O
corresponds,O
to,O
the,O
time,O
required,O
during,O
vi,O
‐,O
ral,O
growth,O
to,O
go,O
from,O
Ct,O
values,O
of,O
40,NUMBER
to,O
34,NUMBER
.,O
While,O
this,O
time,O
win,O
‐,O
dow,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
is,O
not,O
yet,O
rigorously,O
defined,O
.,O
for,O
other,O
res,O
‐,O
piratory,O
viruses,O
such,O
as,O
influenza,CAUSE_OF_DEATH
.,O
and,O
in,O
ferret,O
models,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
transmission,O
.,O
it,O
is,O
on,O
the,O
order,O
of,O
a,DURATION
day,DURATION
[,O
14,NUMBER
.,O
15,NUMBER
],O
.,O
Final,O
‐,O
ly,O
.,O
high,O
‐,O
sensitivity,O
screening,O
tests,O
.,O
when,O
applied,O
during,O
the,O
vi,O
‐,O
ral,O
decline,O
accompanying,O
recovery,O
.,O
are,O
unlikely,O
to,O
substantially,O
impact,O
transmission,O
because,O
such,O
individuals,O
detected,O
have,O
low,O
.,O
if,O
any,O
.,O
infectiousness,O
[,O
10,NUMBER
],O
.,O
To,O
examine,O
how,O
surveillance,O
testing,O
would,O
reduce,O
the,O
average,O
infectiousness,O
of,O
individuals,O
.,O
we,O
first,ORDINAL
modeled,O
the,O
viral,O
loads,O
and,O
infectiousness,O
curves,O
of,O
10.000,NUMBER
simu,O
‐,O
lated,O
individuals,O
using,O
the,O
predicted,O
viral,O
trajectories,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infections,CAUSE_OF_DEATH
based,O
on,O
key,O
features,O
of,O
latency,O
.,O
growth,O
.,O
with,O
‐,O
in,O
‐,O
host,TITLE
viral,O
kinetics,O
.,O
we,O
calculated,O
what,O
percentage,O
of,O
their,O
total,O
infectiousness,O
would,O
be,O
frequencies,O
.,O
Here,O
.,O
infectiousness,O
was,O
taken,O
to,O
be,O
proportional,O
to,O
the,O
logarithm,O
of,O
viral,O
load,O
in,O
excess,O
of,O
106,NUMBER
cp,O
/,O
ml,O
(,O
with,O
alternative,O
assumptions,O
addressed,O
in,O
Supplemental,O
Materials,O
),O
.,O
consistent,O
with,O
the,O
observation,O
that,O
pre,O
‐,O
symptomatic,O
patients,O
are,O
most,O
infectious,O
just,O
prior,O
to,O
the,O
onset,O
of,O
symptoms,O
[,O
4,NUMBER
],O
.,O
and,O
evidence,O
that,O
the,O
efficiency,O
of,O
viral,O
transmission,O
coincides,O
with,O
peak,O
viral,O
loads,O
.,O
which,O
was,O
also,O
identified,O
during,O
the,O
related,O
2003,DATE
SARS,O
outbreak,O
[,O
16,NUMBER
.,O
17,NUMBER
],O
.,O
We,O
considered,O
that,O
20,PERCENT
%,PERCENT
of,O
patients,O
would,O
undergo,O
symptomatic,O
isola,O
‐,O
tion,O
near,O
their,O
peak,O
viral,O
load,O
if,O
they,O
had,O
not,O
viral,O
load,O
posi,O
‐,O
tive,O
test,O
&,O
dx,O
returned,O
days,DURATION
since,O
exposure,O
rel,O
.,O
infectiousness,O
infectiousness,O
removed,O
no,O
test,O
isolated,O
&,O
removed,O
but,O
isolated,O
indiv,O
.,O
infectiousness,O
arbitrary,O
units,O
log10,O
viral,O
load,O
diagnosed,O
.,O
LOD,O
103,NUMBER
diagnosed,O
.,O
LOD,O
105,DURATION
days,DURATION
since,O
exposure,O
no,O
test,O
is,O
shown,O
with,O
LOD,O
thresholds,O
of,O
two,NUMBER
tests,O
.,O
and,O
a,O
hypothetical,O
positive,O
test,O
on,O
day,DURATION
6,NUMBER
.,O
two,DURATION
days,DURATION
after,O
peak,O
viral,O
load,O
.,O
20,NUMBER
other,O
stochas,O
‐,O
tically,O
generated,O
viral,O
loads,O
are,O
shown,O
to,O
highlight,O
trajectory,O
diversity,O
(,O
light,O
grey,O
;,O
see,O
Methods,O
),O
.,O
(,O
B,O
),O
Relative,O
infectiousness,O
for,O
the,O
viral,O
load,O
shown,O
in,O
panel,O
A,O
pre,O
‐,O
test,O
.,O
totaling,O
31,PERCENT
%,PERCENT
(,O
blue,O
),O
and,O
post,O
‐,O
isolation,O
.,O
totaling,O
69,PERCENT
%,PERCENT
(,O
black,O
),O
.,O
(,O
C,O
),O
Surveillance,O
pro,O
‐,O
grams,O
using,O
tests,O
at,O
LODs,O
of,O
103,NUMBER
and,O
105,NUMBER
at,O
frequencies,O
indicated,O
were,O
applied,O
to,O
10,NUMBER
.,O
000,NUMBER
individuals,O
trajectories,O
of,O
whom,O
20,PERCENT
%,PERCENT
would,O
undergo,O
symptomatic,O
isolation,O
near,O
their,O
peak,O
viral,O
load,O
if,O
they,O
had,O
not,O
been,O
tested,O
and,O
isolated,O
first,ORDINAL
.,O
Total,O
infectiousness,O
removed,O
during,O
surveillance,O
(,O
colors,O
),O
and,O
self,O
isolation,O
(,O
hatch,O
),O
are,O
shown,O
for,O
surveillance,O
as,O
indicated,O
.,O
relative,O
to,O
total,O
infec,O
‐,O
tiousness,O
with,O
no,O
surveillance,O
or,O
self,O
‐,O
isolation,O
.,O
(,O
D,O
),O
The,O
impact,O
of,O
surveillance,O
on,O
the,O
infectiousness,O
of,O
100,NUMBER
individuals,O
is,O
shown,O
for,O
each,O
surveillance,O
program,O
and,O
no,O
testing,O
.,O
as,O
indicated,O
.,O
with,O
each,O
individual,O
colored,O
by,O
test,O
if,O
their,O
infection,CAUSE_OF_DEATH
was,O
detected,O
during,O
infectiousness,O
(,O
medians,O
.,O
black,O
lines,O
),O
or,O
colored,O
blue,O
if,O
their,O
infection,CAUSE_OF_DEATH
was,O
missed,O
by,O
surveillance,O
or,O
detected,O
positive,O
after,O
their,O
infectious,O
period,O
(,O
medians,O
.,O
blue,O
lines,O
),O
.,O
Units,O
are,O
arbitrary,O
and,O
scaled,O
to,O
the,O
maximum,O
infectiousness,O
of,O
sampled,O
in,O
‐,O
dividuals,O
.,O
been,O
tested,O
and,O
isolated,O
first,ORDINAL
.,O
and,PERCENT
80,PERCENT
%,PERCENT
would,O
have,O
sufficiently,O
mild,O
or,O
no,O
symptoms,O
such,O
that,O
they,O
would,O
not,O
isolate,O
unless,O
they,O
were,O
detected,O
by,O
surveillance,O
testing,O
.,O
This,O
analysis,O
demonstrated,O
that,O
there,O
was,O
little,O
difference,O
in,O
averting,O
infec,O
‐,O
tiousness,O
between,O
the,O
two,NUMBER
classes,O
of,O
test,O
.,O
Dramatic,O
reductions,O
in,O
total,O
infectiousness,O
of,O
the,O
individuals,O
were,O
observed,O
by,O
testing,O
daily,SET
or,O
every,O
third,ORDINAL
Because,O
viral,O
loads,O
and,O
infectiousness,O
vary,O
across,O
individuals,O
.,O
we,O
also,O
analyzed,O
the,O
impact,O
of,O
Above,O
.,O
we,O
as,O
‐,O
sumed,O
that,O
each,O
infection,CAUSE_OF_DEATH
was,O
independent,RELIGION
.,O
To,O
investigate,O
the,O
ef,O
‐,O
fects,O
of,O
surveillance,O
testing,O
strategies,O
at,O
the,O
population,O
level,O
.,O
we,O
used,O
simulations,O
to,O
monitor,O
whether,O
epidemics,O
were,O
contained,O
or,O
became,O
uncontrolled,O
.,O
while,O
varying,O
the,O
frequencies,O
at,O
which,O
the,O
test,O
was,O
administered,O
.,O
ranging,O
from,O
daily,SET
testing,O
to,O
testing,O
every,SET
14,SET
days,SET
.,O
and,O
considering,O
tests,O
with,O
LOD,O
of,O
103,NUMBER
and,O
105,NUMBER
.,O
analogous,O
to,O
RT,O
‐,O
qPCR,O
and,O
RT,O
‐,O
LAMP,O
/,O
rapid,O
antigen,O
tests,O
.,O
respec,O
‐,O
tively,O
.,O
We,O
used,O
two,NUMBER
different,O
epidemiological,O
models,O
to,O
ensure,O
that,O
important,O
observations,O
were,O
independent,RELIGION
of,O
the,O
specific,O
mod,O
‐,O
eling,O
approach,O
.,O
The,O
first,ORDINAL
model,TITLE
is,O
a,O
previously,DATE
described,O
agent,O
‐,O
based,O
model,TITLE
with,O
total,O
infections,CAUSE_OF_DEATH
fully,O
mixed,O
model,TITLE
reduction,O
in,O
R,O
fully,O
mixed,O
model,TITLE
total,O
infections,CAUSE_OF_DEATH
agent,O
based,O
model,TITLE
reduction,O
in,O
R,O
agent,O
based,O
model,TITLE
no,O
test,O
no,O
test,O
row,O
),O
and,O
agent,O
based,O
model,TITLE
(,O
bottom,O
row,O
),O
are,O
affected,O
by,O
surveillance,O
programs,O
.,O
(,O
A,O
.,O
B,O
),O
More,O
frequent,O
testing,O
reduces,O
the,O
effective,O
reproductive,O
number,O
R,O
.,O
shown,O
as,O
the,O
percentage,O
by,O
which,O
R0,O
is,O
reduced,O
.,O
100,NUMBER
(,O
R0,O
R,O
),O
/,O
R0,O
.,O
Values,O
of,O
R,O
were,O
estimated,O
from,O
50,NUMBER
independent,RELIGION
simulations,O
of,O
dy,O
‐,O
namics,O
(,O
see,O
Methods,O
),O
.,O
(,O
C,O
.,O
D,O
),O
Relative,O
to,O
no,O
testing,O
(,O
grey,O
bars,O
),O
.,O
surveillance,O
suppresses,O
the,O
total,O
number,O
of,O
infections,CAUSE_OF_DEATH
in,O
both,O
models,O
when,O
testing,O
every,SET
day,SET
or,O
every,SET
three,SET
days,SET
.,O
but,O
only,O
par,O
‐,O
tially,O
mitigates,O
total,O
cases,O
for,O
weekly,SET
or,O
bi,O
‐,O
weekly,SET
testing,O
.,O
Er,O
‐,O
ror,O
bars,O
indicate,O
inner,O
95,PERCENT
%,PERCENT
quantiles,O
of,O
50,NUMBER
independent,RELIGION
simula,O
‐,O
tions,O
each,O
.,O
both,O
within,O
‐,O
household,O
and,O
age,O
‐,O
stratified,O
contact,O
structure,O
based,O
on,O
census,O
microdata,O
in,O
a,O
city,O
representative,TITLE
of,O
New,CITY
York,CITY
City,CITY
[,O
18,NUMBER
],O
.,O
and,O
initialized,O
with,O
100,NUMBER
cases,O
without,O
addi,O
‐,O
tional,O
external,O
infections,CAUSE_OF_DEATH
.,O
The,O
second,ORDINAL
model,TITLE
is,O
a,O
simple,O
fully,O
mixed,O
model,TITLE
representing,O
a,O
population,O
of,O
20.000,NUMBER
.,O
to,O
one,NUMBER
new,O
im,O
‐,O
port,O
per,O
day,DURATION
.,O
Individual,O
viral,O
loads,O
were,O
simulated,O
for,O
each,O
in,O
‐,O
fection,O
.,O
and,O
individuals,O
who,O
received,O
a,O
positive,O
test,O
result,O
were,O
isolated,O
.,O
but,O
contact,O
tracing,O
and,O
monitoring,O
was,O
not,O
included,O
to,O
more,O
conservatively,O
estimate,O
the,O
impacts,O
of,O
surveillance,O
alone,O
[,O
19,NUMBER
.,O
20,NUMBER
],O
.,O
Model,TITLE
details,O
and,O
parameters,O
are,O
fully,O
described,O
in,O
Methods,O
.,O
We,O
observed,O
that,O
a,O
surveillance,O
program,O
administering,O
either,O
test,O
with,O
high,O
frequency,O
limited,O
Methods,O
for,O
calculation,O
procedure,O
),O
and,O
by,O
the,O
total,O
infections,CAUSE_OF_DEATH
that,O
persisted,O
in,O
spite,O
of,O
different,O
was,O
found,O
to,O
be,O
the,O
primary,O
driver,TITLE
of,O
population,O
‐,O
level,O
epidemic,O
control,O
.,O
with,O
only,O
a,O
small,O
margin,O
of,O
improvement,O
provid,O
‐,O
ed,O
by,O
using,O
a,O
more,O
sensitive,O
test,O
.,O
Direct,O
examination,O
of,O
simula,O
‐,O
tions,O
showed,O
that,O
with,O
no,O
surveillance,O
or,O
biweekly,SET
testing,O
.,O
in,O
‐,O
fections,O
were,O
uncontrolled,O
.,O
whereas,O
surveillance,O
testing,O
weekly,SET
with,O
either,O
LOD,O
=,O
103,NUMBER
or,O
105,NUMBER
effectively,O
attenuated,O
surges,O
of,O
in,O
‐,O
fections,O
(,O
examples,O
The,O
relationship,O
between,O
test,O
sensitivity,O
and,O
the,O
frequency,O
of,O
testing,O
required,O
to,O
control,O
outbreaks,O
in,O
both,O
the,O
fully,O
mixed,O
model,TITLE
and,O
the,O
agent,O
‐,O
based,O
model,TITLE
generalize,O
beyond,O
the,O
examples,O
shown,O
in,O
viral,O
load,O
test,O
sample,O
positive,O
dx,O
rel,O
.,O
in,O
‐,O
fectiousness,O
infectiousness,O
removed,O
days,DURATION
since,O
exposure,O
awaiting,O
dx,O
but,O
isolated,O
isolated,O
&,O
removed,O
indiv,O
.,O
infectiousness,O
arbi,O
‐,O
trary,O
units,O
log10,O
viral,O
load,O
no,O
test,O
daily,SET
diagnosed,O
.,O
LOD,O
103,NUMBER
di,O
‐,O
agnosed,O
.,O
LOD,ORGANIZATION
105,NUMBER
missed,O
/,O
caught,O
late,DURATION
days,DURATION
since,O
exposure,O
no,O
test,O
viral,O
load,O
trajectory,O
is,O
shown,O
with,O
LOD,O
thresholds,O
of,O
two,NUMBER
tests,O
.,O
and,O
a,O
hypothetical,O
positive,O
test,O
on,O
day,DURATION
6,NUMBER
.,O
but,O
with,O
results,O
re,O
‐,O
ported,O
on,O
day,DURATION
8,NUMBER
.,O
20,NUMBER
other,O
stochastically,O
generated,O
viral,O
loads,O
are,O
shown,O
to,O
highlight,O
trajectory,O
diversity,O
(,O
light,O
grey,O
;,O
see,O
Methods,O
),O
.,O
(,O
B,O
),O
Relative,O
infectiousness,O
for,O
the,O
viral,O
load,O
shown,O
in,O
panel,O
A,O
pretest,O
(,O
totaling,O
31,PERCENT
%,PERCENT
;,O
blue,O
),O
and,O
post,O
‐,O
test,O
but,O
pre,O
‐,O
diag,O
‐,O
nosis,O
(,O
totaling,O
32,PERCENT
%,PERCENT
;,O
green,O
),O
.,O
and,O
post,O
‐,O
isolation,O
(,O
totaling,O
37,PERCENT
%,PERCENT
;,O
black,O
),O
.,O
(,O
C,O
),O
Surveillance,O
programs,O
using,O
tests,O
at,O
LODs,O
of,O
103,NUMBER
and,O
105,NUMBER
at,O
frequencies,O
indicated,O
.,O
and,O
with,O
results,O
returned,O
after,O
0,NUMBER
.,O
1,NUMBER
.,O
or,O
2,DURATION
days,DURATION
(,O
indicated,O
by,O
small,O
text,O
beneath,O
bars,O
),O
were,O
applied,O
to,O
10,NUMBER
.,O
000,NUMBER
individuals,O
trajectories,O
of,O
whom,O
20,PERCENT
%,PERCENT
were,O
symptomatic,O
and,O
self,O
‐,O
isolated,O
after,O
peak,O
viral,O
load,O
if,O
they,O
had,O
not,O
been,O
tested,O
and,O
isolated,O
first,ORDINAL
.,O
Total,O
infectiousness,O
removed,O
during,O
surveillance,O
(,O
colors,O
),O
and,O
self,O
isolation,O
(,O
hatch,O
),O
are,O
shown,O
.,O
rela,O
‐,O
tive,O
to,O
total,O
infectiousness,O
with,O
no,O
surveillance,O
or,O
self,O
‐,O
isola,O
‐,O
tion,O
.,O
Delays,O
substantially,O
impact,O
the,O
fraction,O
of,O
infectiousness,O
removed,O
.,O
(,O
D,O
),O
The,O
impact,O
of,O
surveillance,O
with,O
delays,O
in,O
returning,O
diagnosis,O
of,O
0,NUMBER
.,O
1,NUMBER
.,O
or,O
2,DURATION
days,DURATION
(,O
small,O
text,O
beneath,O
axis,O
),O
on,O
the,O
in,O
‐,O
fectiousness,O
of,O
100,NUMBER
individuals,O
is,O
shown,O
for,O
each,O
surveillance,O
program,O
and,O
no,O
testing,O
.,O
as,O
indicated,O
.,O
with,O
each,O
individual,O
col,O
‐,O
ored,O
by,O
test,O
if,O
their,O
infection,CAUSE_OF_DEATH
was,O
detected,O
during,O
infectious,O
‐,O
ness,O
(,O
medians,O
.,O
black,O
lines,O
),O
or,O
colored,O
blue,O
if,O
their,O
infection,CAUSE_OF_DEATH
was,O
missed,O
by,O
surveillance,O
or,O
diagnosed,O
positive,O
after,O
their,O
in,O
‐,O
fectious,O
period,O
(,O
medians,O
.,O
blue,O
lines,O
),O
.,O
Units,O
are,O
arbitrary,O
and,O
scaled,O
to,O
the,O
maximum,O
infectiousness,O
of,O
sampled,O
individuals,O
.,O
at,O
LODs,O
of,O
103,NUMBER
.,O
105,NUMBER
.,O
and,NUMBER
106,NUMBER
.,O
and,O
for,O
testing,O
ranging,O
from,O
daily,SET
to,O
every,SET
14,SET
days,SET
.,O
For,O
those,O
.,O
To,O
address,O
whether,O
these,O
finding,O
are,O
sensitive,O
to,O
this,O
modeled,O
relationship,O
.,O
we,O
performed,O
similar,O
be,O
‐,O
tween,O
infectiousness,O
and,O
viral,O
load,O
.,O
An,O
important,O
variable,O
in,O
surveillance,O
testing,O
is,O
the,O
time,O
between,O
a,O
tests,O
sample,O
collec,O
‐,O
tion,O
and,O
the,O
reporting,O
of,O
a,O
diagnosis,O
.,O
To,O
examine,O
how,O
time,O
to,O
re,O
‐,O
porting,O
affected,O
epidemic,O
control,O
.,O
we,O
re,O
‐,O
analyzed,O
both,O
the,O
reduc,O
‐,O
tion,O
in,O
individuals,O
infectiousness,O
.,O
as,O
well,O
as,O
the,O
epidemiologi,O
‐,O
cal,O
sim5,O
reduction,O
in,O
R,O
agent,O
based,O
model,TITLE
total,O
infections,CAUSE_OF_DEATH
fully,O
mixed,O
model,TITLE
dx,O
delay,O
no,O
test,O
daily,SET
total,O
infections,CAUSE_OF_DEATH
agent,O
based,O
model,TITLE
reduction,O
in,O
R,O
fully,O
mixed,O
model,TITLE
no,O
test,O
daily,SET
The,O
effec,O
‐,O
tiveness,O
of,O
surveillance,O
programs,O
are,O
dramatically,O
diminished,O
by,O
delays,O
in,O
reporting,O
in,O
both,O
the,O
fully,O
‐,O
mixed,O
compartmental,O
model,TITLE
(,O
top,O
row,O
),O
and,O
agent,O
based,O
model,TITLE
(,O
bottom,O
row,O
),O
.,O
(,O
A,O
.,O
B,O
),O
The,O
impact,O
of,O
surveillance,O
every,SET
day,SET
.,O
3,DURATION
days,DURATION
.,O
weekly,SET
.,O
or,O
biweekly,SET
.,O
on,O
the,O
reproductive,O
number,O
R,O
.,O
calculated,O
as,O
100,NUMBER
(,O
R0,O
R,O
),O
/,O
R0,O
.,O
is,O
shown,O
for,O
LODs,O
103,NUMBER
and,O
105,NUMBER
and,O
delays,O
of,O
0,NUMBER
.,O
1,NUMBER
.,O
or,O
2,DURATION
days,DURATION
(,O
small,O
text,O
below,O
axis,O
),O
.,O
Values,O
of,O
R,O
were,O
estimated,O
from,O
50,NUMBER
independent,RELIGION
simu,O
‐,O
lations,O
of,O
dynamics,O
(,O
see,O
Methods,O
),O
.,O
(,O
C,O
.,O
D,O
),O
Relative,O
to,O
no,O
testing,O
(,O
grey,O
bars,O
),O
.,O
surveillance,O
suppresses,O
the,O
total,O
number,O
of,O
infec,O
‐,O
tions,O
in,O
both,O
models,O
when,O
testing,O
every,SET
day,SET
or,O
every,SET
three,SET
days,SET
.,O
but,O
delayed,O
results,O
lead,O
to,O
only,O
partial,O
mitigation,O
of,O
total,O
cas,O
‐,O
es,O
.,O
even,O
for,O
testing,O
every,SET
day,SET
or,O
3,DURATION
days,DURATION
.,O
Error,O
bars,O
indicate,O
in,O
‐,O
ner,O
95,PERCENT
%,PERCENT
quantiles,O
of,O
50,NUMBER
independent,RELIGION
simulations,O
each,O
.,O
ulations,O
.,O
comparing,O
the,O
results,O
of,O
instantaneous,O
reporting,O
(,O
reflecting,O
a,O
rapid,O
point,O
‐,O
of,O
‐,O
care,O
assay,O
),O
.,O
of,O
viral,O
spread,O
and,O
emphasize,O
that,O
fast,O
reporting,O
of,O
results,O
is,O
critical,O
in,O
any,O
surveillance,O
test,O
‐,O
ing,O
.,O
These,O
results,O
also,O
reinforce,O
the,O
relatively,O
smaller,O
bene,O
‐,O
fits,O
of,O
improved,O
limits,O
of,O
detection,O
.,O
Communities,O
vary,O
in,O
their,O
transmission,O
dynamics,O
.,O
due,O
to,O
difference,O
in,O
rates,O
of,O
imported,O
in,O
‐,O
fections,O
and,O
in,O
the,O
basic,O
reproductive,O
number,O
R0,O
.,O
both,O
of,O
which,O
will,O
influence,O
the,O
frequency,O
and,O
sensitivity,O
with,O
which,O
surveil,O
‐,O
lance,O
testing,O
must,O
occur,O
.,O
We,O
performed,O
two,NUMBER
analyses,O
to,O
illustrate,O
this,O
point,O
.,O
First,ORDINAL
.,O
we,O
varied,O
the,O
rate,O
of,O
external,O
infection,CAUSE_OF_DEATH
in,O
our,O
fully,O
mixed,O
model,TITLE
.,O
and,O
confirmed,O
that,O
when,O
the,O
external,O
rate,O
of,O
infection,CAUSE_OF_DEATH
is,O
higher,O
.,O
more,O
frequent,O
surveillance,O
is,O
required,O
to,O
prevent,O
outbreaks,O
and,O
C,O
),O
.,O
This,DATE
may,DATE
be,O
relevant,O
to,O
institutions,O
like,O
college,O
campuses,O
or,O
military,O
bases,O
wherein,O
fre,O
‐,O
quent,O
class,O
‐,O
room,O
setting,O
or,O
dormitory,O
living,O
are,O
likely,O
to,O
increase,O
contact,O
rates,O
.,O
Thus,O
.,O
the,O
specific,O
strategy,O
for,O
successful,O
surveillance,O
will,O
depend,O
on,O
the,O
current,DATE
community,O
infection,CAUSE_OF_DEATH
prevalence,O
and,O
transmission,O
rate,O
.,O
Our,O
results,O
lead,O
us,O
to,O
conclude,O
that,O
surveil,O
‐,O
lance,O
testing,O
of,O
asymptomatic,O
individuals,O
can,O
be,O
used,O
to,O
limit,O
the,O
spread,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
However,O
.,O
our,O
findings,O
are,O
subject,O
to,O
a,O
number,O
of,O
limitations,O
.,O
First,ORDINAL
.,O
the,O
sensitivity,O
of,O
a,O
test,O
may,O
de,O
‐,O
pend,O
on,O
factors,O
beyond,O
LOD,CITY
.,O
including,O
manufacturer,TITLE
variation,O
and,O
improper,O
clinical,O
sampling,O
[,O
21,NUMBER
],O
.,O
though,O
the,O
latter,O
may,O
be,O
amelio,O
‐,O
rated,O
by,O
different,O
approaches,O
to,O
sample,O
collection,O
.,O
such,O
as,O
sali,O
‐,O
va,O
‐,O
based,O
testing,O
[,O
22,NUMBER
],O
.,O
Second,ORDINAL
.,O
our,O
model,TITLE
assumed,O
that,O
no,O
individ,O
‐,O
uals,O
would,O
refuse,O
testing,O
.,O
Both,O
refusal,O
and,O
sampling,O
‐,O
driven,O
sen,O
‐,O
sitivity,O
issues,O
can,O
be,O
accounted,O
for,O
in,O
estimates,O
using,O
a,O
simple,O
formula,O
(,O
see,O
Supplemental,O
Text,O
),O
.,O
but,O
a,O
more,O
sophisticated,O
under,O
‐,O
standing,O
of,O
the,O
relationship,O
between,O
sampling,O
‐,O
driven,O
sensitivity,O
issues,O
and,O
viral,O
load,O
.,O
for,O
instance,O
.,O
would,O
more,O
accurately,O
ad,O
‐,O
dress,O
this,O
limitation,O
.,O
Finally,O
.,O
the,O
exact,O
performance,O
differences,O
between,O
testing,O
schemes,O
will,O
depend,O
on,O
whether,O
our,O
model,TITLE
truly,O
captures,O
viral,O
kinetics,O
and,O
infectiousness,O
profiles,O
[,O
4,NUMBER
],O
.,O
particu,O
‐,O
larly,O
during,O
the,O
acceleration,O
phase,O
between,O
exposure,O
and,O
peak,O
vi,O
‐,O
ral,O
load,O
.,O
Continued,O
clarification,O
of,O
these,O
within,O
‐,O
host,TITLE
dynamics,O
would,O
increase,O
the,O
impact,O
and,O
value,O
of,O
this,O
.,O
and,O
other,O
[,O
19,NUMBER
.,O
20,NUMBER
],O
modeling,O
studies,O
.,O
A,O
critical,O
point,O
is,O
that,O
the,O
requirements,O
for,O
surveillance,O
testing,O
are,O
distinct,O
from,O
clinical,O
testing,O
.,O
Clini,O
‐,O
cal,O
diagnoses,O
target,O
symptomatic,O
individuals,O
.,O
need,O
high,O
accuracy,O
and,O
sensitivity,O
.,O
and,O
are,O
not,O
limited,O
by,O
cost,O
.,O
Because,O
they,O
focus,O
on,O
symptomatic,O
individuals,O
.,O
those,O
individuals,O
can,O
isolate,O
such,O
that,O
a,O
diagnosis,O
delay,O
does,O
not,O
lead,O
to,O
additional,O
infections,CAUSE_OF_DEATH
.,O
In,O
contrast,O
.,O
results,O
from,O
the,O
surveillance,O
testing,O
of,O
asymptomatic,O
individuals,O
need,O
to,O
be,O
returned,O
quickly,O
.,O
since,O
even,O
a,O
single,O
day,DURATION
diagnosis,O
delay,O
compromises,O
the,O
surveillance,O
programs,O
effective,O
‐,O
ness,O
.,O
Indeed,O
.,O
at,O
least,O
for,O
viruses,O
with,O
infection,CAUSE_OF_DEATH
kinetics,O
simi,O
‐,O
lar,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
we,O
find,O
that,O
speed,O
of,O
reporting,O
is,O
much,O
more,O
important,O
than,O
sensitivity,O
.,O
althoughmore,O
sensitive,O
testsare,O
nev,O
‐,O
erthelesssomewhat,O
more,O
effective,O
.,O
The,O
difference,O
between,O
clini,O
‐,O
cal,O
and,O
surveillance,O
testing,O
highlights,O
the,O
need,O
for,O
additional,O
tests,O
to,O
be,O
approved,O
and,O
utilized,O
for,O
surveillance,O
.,O
Such,O
tests,O
should,O
not,O
be,O
held,O
to,O
the,O
same,O
degree,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
assays,O
.,O
We,O
suggest,O
that,O
the,O
FDA,ORGANIZATION
.,O
other,O
agencies,O
.,O
or,O
state,O
governments,O
.,O
en,O
‐,O
courage,O
the,O
development,O
and,O
use,O
of,O
alternative,O
faster,O
and,O
lower,O
cost,O
tests,O
for,O
surveillance,O
purposes,O
.,O
even,O
if,O
they,O
have,O
poorer,O
limits,O
of,O
detection,O
.,O
If,O
the,O
availability,O
of,O
point,O
‐,O
of,O
‐,O
care,O
or,O
self,O
‐,O
administered,O
surveillance,O
tests,O
leads,O
to,O
faster,O
turnaround,O
time,O
or,O
more,O
frequent,O
testing,O
.,O
our,O
results,O
suggest,O
that,O
they,O
would,O
have,O
high,O
epidemiological,O
value,O
.,O
Our,O
modeling,O
suggests,O
that,O
some,O
types,O
of,O
surveillance,O
will,O
subject,O
some,O
individuals,O
to,O
unnecessary,O
quarantine,O
days,DURATION
.,O
For,O
instance,O
.,O
the,O
infrequent,O
use,O
of,O
a,O
sensitive,O
test,O
will,O
not,O
only,O
identify,O
(,O
i,O
),O
those,O
with,O
a,O
low,O
vi,O
‐,O
ral,O
load,O
in,O
the,O
beginning,O
of,O
the,O
infection,CAUSE_OF_DEATH
.,O
who,O
must,O
be,O
isolated,O
to,O
limit,O
viral,O
the,O
infectious,O
threshold,O
[,O
9,NUMBER
.,O
10,NUMBER
],O
.,O
Isolating,O
this,O
second,ORDINAL
group,O
of,O
patients,O
will,O
have,O
no,O
impact,O
on,O
viral,O
spread,O
but,O
will,O
incur,O
costs,O
of,O
isolation,O
.,O
The,O
use,O
of,O
serology,O
.,O
repeat,O
test,O
‐,O
ing,O
24,NUMBER
or,O
48,DURATION
hours,DURATION
apart,O
.,O
or,O
some,O
other,O
test,O
.,O
to,O
distinguish,O
low,O
viral,O
load,O
patients,O
on,O
the,O
upslope,O
of,O
infection,CAUSE_OF_DEATH
from,O
those,O
in,O
the,O
recovery,O
phase,O
could,O
allow,O
for,O
more,O
effective,O
quarantine,O
deci,O
‐,O
sions,O
.,O
grants,O
NIH,ORGANIZATION
F32,O
AI145112,O
(,O
James,PERSON
Burke,PERSON
),O
.,O
NIH,ORGANIZATION
F30,O
AG063468,O
(,O
Evan,PERSON
Lester,PERSON
),O
.,O
MURI,O
W911NF17,O
‐,O
1,NUMBER
‐,O
0370,DATE
(,O
Milind,PERSON
Tambe,PERSON
),O
.,O
an,O
NIH,O
direc,O
‐,O
tors,O
DP5,O
award,O
1DP5OD028145,O
‐,O
01,NUMBER
(,O
Michael,PERSON
Mina,PERSON
),O
.,O
and,O
[,O
1,NUMBER
],O
Melissa,PERSON
M,PERSON
Arons,PERSON
.,O
Kelly,PERSON
M,PERSON
Hatfield,PERSON
.,O
Sujan,PERSON
C,PERSON
Reddy,PERSON
.,O
Anne,PERSON
Kimball,PERSON
.,O
Allison,PERSON
James,PERSON
.,O
Jesica,PERSON
R,PERSON
Jacobs,PERSON
.,O
Joanne,PERSON
Taylor,PERSON
.,O
Kevin,PERSON
Spicer,PERSON
.,O
Ana,PERSON
C,O
Bar,O
‐,O
dossy,O
.,O
Lisa,PERSON
P,PERSON
Oakley,PERSON
.,O
et,O
al,O
.,O
Presymptomatic,MISC
of,MISC
Medicine,MISC
.,O
2020,DATE
.,O
[,O
2,NUMBER
],O
Desmond,PERSON
Sutton,PERSON
.,O
Karin,PERSON
Fuchs,PERSON
.,O
Mary,PERSON
Dalton,PERSON
.,O
and,O
Dena,PERSON
Goffman,PERSON
.,O
Universal,O
screening,O
for,O
[,O
3,NUMBER
],O
Daniel,PERSON
P,PERSON
Oran,PERSON
and,O
Eric,PERSON
J,PERSON
Topol,PERSON
.,O
Prevalence,O
of,O
asymptomatic,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
:,O
A,O
[,O
4,NUMBER
],O
Xi,O
He,O
.,O
Er,O
‐,O
ic,O
HY,PERSON
Lau,PERSON
.,O
Peng,PERSON
Wu,PERSON
.,O
Xilong,PERSON
Deng,PERSON
.,O
Jian,PERSON
Wang,PERSON
.,O
Xinxin,PERSON
Hao,PERSON
.,O
Yiu,PERSON
Chung,PERSON
Lau,PERSON
.,O
Jessica,PERSON
Y,PERSON
Wong,PERSON
.,O
Yujuan,PERSON
Guan,PERSON
.,O
Xinghua,PERSON
Tan,PERSON
.,O
et,O
al,O
.,O
Temporal,O
dynamics,O
in,O
viral,O
shedding,O
and,O
transmissibility,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
Na,O
‐,O
ture,O
Medicine,O
.,O
26,NUMBER
(,O
5,NUMBER
),O
:,O
672675,NUMBER
.,O
2020,DATE
.,O
[,O
5,NUMBER
],O
Chantal,PERSON
BF,PERSON
Vogels,PERSON
.,O
Ander,PERSON
‐,PERSON
son,O
F,PERSON
Brito,PERSON
.,O
Anne,PERSON
Louise,PERSON
Wyllie,PERSON
.,O
Joseph,PERSON
R,PERSON
Fauver,PERSON
.,O
Isabel,PERSON
M,PERSON
Ott,PERSON
.,O
Chaney,PERSON
C,PERSON
Kalinich,PERSON
.,O
Mary,PERSON
E,PERSON
Petrone,PERSON
.,O
Marie,PERSON
‐,PERSON
Louise,PERSON
Landry,PERSON
.,O
Ellen,PERSON
F,PERSON
Foxman,PERSON
.,O
and,O
Nathan,PERSON
D,PERSON
Grubaugh,PERSON
.,O
Analytical,O
sensitivity,O
and,O
effi,O
‐,O
ciency,O
comparisons,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
qRT,O
‐,O
PCR,O
assays,O
.,O
medRxiv,O
.,O
2020,DATE
.,O
[,O
6,NUMBER
],O
Coronavirus,O
(,O
COVID,O
‐,O
19,NUMBER
),O
update,O
:,O
FDA,ORGANIZATION
informs,O
public,O
about,O
pos,O
‐,O
sible,O
accuracy,O
concerns,O
with,O
Abbott,ORGANIZATION
ID,STATE_OR_PROVINCE
NOW,DATE
Point,O
‐,O
of,O
‐,O
Care,O
Test,O
.,O
[,O
7,NUMBER
],O
Kendra,PERSON
Quicke,PERSON
.,O
Emily,PERSON
Gallichote,PERSON
.,O
Nicole,PERSON
Sexton,PERSON
.,O
Michael,PERSON
Young,O
.,O
Ashley,PERSON
Janich,PERSON
.,O
Gregory,PERSON
Gahm,PERSON
.,O
Elizabeth,PERSON
J,PERSON
Carlton,PERSON
.,O
Nicole,PERSON
Ehrhart,PERSON
.,O
and,O
Gregory,PERSON
D,PERSON
Ebel,PERSON
.,O
Longitudinal,O
surveillance,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
RNA,O
among,O
asymptomatic,O
staff,O
in,O
five,NUMBER
colorado,STATE_OR_PROVINCE
skilled,O
nurs,O
‐,O
ing,O
facilities,O
:,O
Epidemiologic,O
.,O
virologic,O
and,O
sequence,O
analysis,O
.,O
medRxiv,O
.,O
2020,DATE
.,O
[,O
8,NUMBER
],O
Roman,PERSON
Wolfel,PERSON
.,O
Victor,PERSON
M,PERSON
Corman,PERSON
.,O
Wolfgang,PERSON
Guggemos,PERSON
.,O
Michael,PERSON
Seilmaier,PERSON
.,O
Sabine,PERSON
Zange,PERSON
.,O
Marcel,PERSON
A,PERSON
Muller,PERSON
.,O
Daniela,PERSON
Niemeyer,PERSON
.,O
Terry,PERSON
C,PERSON
Jones,PERSON
.,O
Patrick,PERSON
Vollmar,PERSON
.,O
Camilla,PERSON
Rothe,PERSON
.,O
et,O
al,O
.,O
Virological,O
assessment,O
of,O
hospitalized,O
patients,O
with,O
COVID,O
‐,O
2019,DATE
.,O
Nature,O
.,O
581,NUMBER
(,O
7809,NUMBER
),O
:,O
465,NUMBER
[,O
9,NUMBER
],O
Bernard,PERSON
La,PERSON
Scola,PERSON
.,O
Marion,PERSON
Le,PERSON
Bideau,PERSON
.,O
Julien,PERSON
Andreani,PERSON
.,O
Van,PERSON
Thuan,PERSON
Hoang,PERSON
.,O
Clio,PERSON
Grimaldier,PERSON
.,O
Philippe,PERSON
Colson,PERSON
.,O
Philippe,PERSON
Gautret,PERSON
.,O
and,O
Didier,PERSON
Raoult,PERSON
.,O
Viral,O
RNA,O
load,O
as,O
determined,O
by,O
cell,O
culture,O
as,O
a,O
management,O
tool,O
for,O
dis,O
‐,O
charge,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
patients,O
from,O
infectious,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
[,O
10,NUMBER
],O
Soren,PERSON
Alexandersen,PERSON
.,O
Anthony,PERSON
Chamings,PERSON
.,O
and,O
Tarka,PERSON
Raj,PERSON
Bhatta,PERSON
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
genomic,O
and,O
subgenomic,O
RNAs,O
in,O
diagnostic,O
samples,O
are,O
not,O
an,O
in,O
‐,O
dicator,O
of,O
active,O
replication,O
.,O
medRxiv,O
.,O
[,O
11,NUMBER
],O
Charles,PERSON
GB,PERSON
Caraguel,PERSON
.,O
Henrik,PERSON
Stryhn,PERSON
.,O
Nellie,PERSON
Gagne,PERSON
.,O
Ian,PERSON
R,PERSON
Dohoo,PERSON
.,O
and,O
K,O
Larry,PERSON
Hammell,PERSON
.,O
Selection,O
of,O
a,O
cutoff,O
value,O
for,O
real,O
‐,O
time,O
polymerase,O
chain,O
reac,O
‐,O
tion,O
results,O
to,O
fit,O
a,O
diagnostic,O
[,O
12,NUMBER
],O
Adrian,PERSON
Ruiz,PERSON
‐,PERSON
Villalba,PERSON
.,O
Eliz,PERSON
‐,PERSON
abeth,O
van,O
Pelt,PERSON
‐,PERSON
Verkuil,PERSON
.,O
Quinn,PERSON
D,PERSON
Gunst,PERSON
.,O
Jan,PERSON
M,PERSON
Ruijter,PERSON
.,O
and,O
Maurice,PERSON
JB,PERSON
van,PERSON
den,PERSON
Hoff,PERSON
.,O
Amplification,O
of,O
nonspecific,O
products,O
in,O
quanti,O
‐,O
tative,O
polymerase,O
chain,O
reactions,O
(,O
qPCR,O
),O
.,O
Biomolecular,O
detection,O
and,O
quantification,O
.,O
14:718,NUMBER
.,O
2017,DATE
.,O
[,O
14,NUMBER
],O
Amber,PERSON
M,PERSON
Smith,PERSON
and,O
Alan,PERSON
S,PERSON
Perelson,PERSON
.,O
Influenza,CAUSE_OF_DEATH
A,O
virus,O
infection,CAUSE_OF_DEATH
kinetics,O
:,O
quantitative,O
data,O
[,O
15,NUMBER
],O
Mathilde,PERSON
Richard,PERSON
.,O
Adinda,PERSON
Kok,PERSON
.,O
Dennis,PERSON
de,PERSON
Meulder,PERSON
.,O
Theo,PERSON
M,PERSON
Bestebroer,PERSON
.,O
Mart,PERSON
M,PERSON
Lamers,PERSON
.,O
Nisreen,PERSON
MA,PERSON
Okba,PERSON
.,O
Martje,PERSON
Fentener,PERSON
van,PERSON
Vlissingen,PERSON
.,O
Barry,PERSON
Rockx,PERSON
.,O
Bart,PERSON
L,PERSON
Haagmans,PERSON
.,O
Marion,PERSON
PG,PERSON
Koopmans,PERSON
.,O
et,O
al,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
is,O
transmitted,O
via,O
contact,O
and,O
via,O
the,O
air,O
between,O
ferrets,O
.,O
bioRxiv,O
.,O
2020,DATE
.,O
[,O
16,NUMBER
],O
Zhuang,PERSON
Shen,PERSON
.,O
Fang,PERSON
Ning,PERSON
.,O
Weigong,PERSON
Zhou,PERSON
.,O
Xiong,PERSON
He,PERSON
.,O
Changying,PERSON
Lin,PERSON
.,O
Daniel,PERSON
P,PERSON
Chin,PERSON
.,O
Zonghan,PERSON
Zhu,PERSON
.,O
and,O
Anne,PERSON
Schuchat,PERSON
.,O
Superspreading,O
sars,O
events,O
.,O
beijing,O
.,O
2003,DATE
.,O
Emerg,O
‐,O
ing,O
Infectious,O
[,O
17,NUMBER
],O
Joseph,PERSON
Sriyal,PERSON
Malik,PERSON
Peiris,PERSON
.,O
Chung,PERSON
‐,PERSON
Ming,PERSON
Chu,PERSON
.,O
Vincent,PERSON
Chi,PERSON
‐,PERSON
Chung,PERSON
Cheng,PERSON
.,O
KS,PERSON
Chan,PERSON
.,O
IFN,ORGANIZATION
Hung,ORGANIZATION
.,O
Leo,PERSON
LM,PERSON
Poon,PERSON
.,O
Kin,O
‐,O
Ip,O
Law,PERSON
.,O
BSF,PERSON
Tang,PERSON
.,O
TYW,O
Hon,O
.,O
CS,PERSON
Chan,PERSON
.,O
et,O
al,O
.,O
Clinical,O
progression,O
and,O
viral,O
load,O
in,O
a,O
community,O
outbreak,O
of,O
coronavirus,O
‐,O
associated,O
sars,O
pneumonia,CAUSE_OF_DEATH
:,O
a,O
prospective,O
study,O
.,O
The,O
Lancet,O
.,O
361,NUMBER
(,O
9371,NUMBER
),O
:,O
17671772,NUMBER
.,O
2003,DATE
.,O
[,O
18,NUMBER
],O
Bryan,PERSON
Wilder,PERSON
.,O
Marie,PERSON
Charpignon,PERSON
.,O
Jackson,PERSON
A,PERSON
Killian,PERSON
.,O
Han,O
‐,O
Ching,O
Ou,O
.,O
Aditya,ORGANIZATION
Mate,ORGANIZATION
.,O
Shahin,PERSON
Jabbari,PERSON
.,O
Andrew,PERSON
Perrault,PERSON
.,O
Angel,PERSON
Desai,PERSON
.,O
Milind,PERSON
Tambe,PERSON
.,O
and,O
Maimuna,PERSON
S,PERSON
Majumder,PERSON
.,O
Modeling,O
between,O
‐,O
population,O
variation,O
in,O
COVID,O
‐,O
19,NUMBER
dynamics,O
in,O
hubei,STATE_OR_PROVINCE
.,O
lombardy,O
.,O
and,O
new,O
york,O
city,O
.,O
Available,O
at,O
SSRN,O
3564800,NUMBER
.,O
2020,DATE
.,O
[,O
19,NUMBER
],O
Corey,PERSON
M,PERSON
Peak,O
.,O
Rebecca,PERSON
Kahn,PERSON
.,O
Yonatan,PERSON
H,PERSON
Grad,PERSON
.,O
Lauren,PERSON
M,PERSON
Childs,PERSON
.,O
Ruoran,PERSON
Li,PERSON
.,O
Marc,PERSON
Lipsitch,PERSON
.,O
and,O
Caroline,PERSON
O,PERSON
Buckee,PERSON
.,O
Individual,O
quarantine,O
ver,O
‐,O
sus,O
active,O
monitoring,O
of,O
contacts,O
for,O
the,O
mitigation,O
of,O
COVID,O
‐,O
19,NUMBER
:,O
a,O
modelling,O
study,O
.,O
The,O
Lancet,O
Infectious,O
Diseases,CAUSE_OF_DEATH
.,O
2020,DATE
.,O
[,O
20,NUMBER
],O
Adam,PERSON
J,PERSON
Kucharski,PERSON
.,O
Petra,PERSON
Klepac,PERSON
.,O
Andrew,PERSON
Conlan,PERSON
.,O
Stephen,PERSON
M,PERSON
Kissler,PERSON
.,O
Maria,PERSON
Tang,PERSON
.,O
Hannah,PERSON
Fry,PERSON
.,O
Julia,PERSON
Gog,PERSON
.,O
John,PERSON
Edmunds,PERSON
.,O
CMMID,O
COVID,O
‐,O
19,NUMBER
Working,ORGANIZATION
Group,ORGANIZATION
.,O
et,O
al,O
.,O
Effectiveness,O
of,O
isolation,O
.,O
testing,O
.,O
con,O
‐,O
tact,O
tracing,O
and,O
physical,O
distancing,O
on,O
reducing,O
transmission,O
of,O
SARSCoV,O
‐,O
2,NUMBER
in,O
different,O
settings,O
.,O
medRxiv,O
.,O
2020,DATE
.,O
[,O
21,NUMBER
],O
Yicheng,PERSON
Fang,PERSON
.,O
Huangqi,PERSON
Zhang,PERSON
.,O
Jicheng,PERSON
Xie,PERSON
.,O
Minjie,PERSON
Lin,PERSON
.,O
Lingjun,PERSON
Ying,PERSON
.,O
Peipei,PERSON
Pang,PERSON
.,O
and,O
[,O
22,NUMBER
],O
Anne,PERSON
Louise,PERSON
Wyllie,PERSON
.,O
John,PERSON
Fournier,PERSON
.,O
Arnau,PERSON
Casanovas,O
‐,O
Massana,PERSON
.,O
Melissa,PERSON
Campbell,PERSON
.,O
Maria,PERSON
Tokuyama,PERSON
.,O
Pavithra,PERSON
Vi,PERSON
‐,O
jayakumar,O
.,O
Bertie,PERSON
Geng,PERSON
.,O
M,O
Catherine,PERSON
Muenker,PERSON
.,O
Adam,PERSON
J,PERSON
Moore,PERSON
.,O
Chan,RELIGION
‐,O
tal,O
BF,O
Vogels,PERSON
.,O
et,O
al,O
.,O
Saliva,O
is,O
more,O
sensitive,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
de,O
‐,O
tection,O
in,O
COVID,O
‐,O
19,NUMBER
patients,O
than,O
nasopharyngeal,O
swabs,O
.,O
Medrxiv,O
.,O
2020,DATE
.,O
[,O
23,NUMBER
],O
Stephen,PERSON
A,PERSON
Lauer,PERSON
.,O
Kyra,PERSON
H,PERSON
Grantz,PERSON
.,O
Qifang,PERSON
Bi,PERSON
.,O
Forrest,PERSON
K,PERSON
Jones,PERSON
.,O
Qulu,PERSON
Zheng,PERSON
.,O
Hannah,PERSON
R,PERSON
Meredith,PERSON
.,O
Andrew,PERSON
S,PERSON
Azman,PERSON
.,O
Nicholas,PERSON
G,PERSON
Reich,PERSON
.,O
and,O
Justin,PERSON
Lessler,PERSON
.,O
The,O
incubation,O
period,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
from,O
publicly,O
reported,O
confirmed,O
cases,O
:,O
estimation,O
and,O
application,O
.,O
Annals,O
of,O
internal,O
medicine,O
.,O
172,NUMBER
(,O
9,NUMBER
),O
:,O
577582,NUMBER
.,O
2020,DATE
.,O
[,O
24,NUMBER
],O
Abishek,PERSON
Chandrashekar,PERSON
.,O
Jinyan,PERSON
Liu,PERSON
.,O
Amanda,PERSON
J,PERSON
Martinot,PERSON
.,O
Katherine,PERSON
McMahan,PERSON
.,O
Noe,PERSON
B,PERSON
Mercado,PERSON
.,O
Lauren,PERSON
Pe,PERSON
‐,PERSON
ter,TITLE
.,O
Lisa,PERSON
H,PERSON
Tostanoski,PERSON
.,O
Jingyou,PERSON
Yu,PERSON
.,O
Zoltan,PERSON
Maliga,PERSON
.,O
Michael,PERSON
Neko,PERSON
‐,PERSON
rchuk,O
.,O
et,O
al,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
protects,O
against,O
rechallenge,O
in,O
rhesus,O
macaques,O
.,O
Science,O
.,O
2020,DATE
.,O
[,O
25,NUMBER
],O
Jingyou,PERSON
Yu,PERSON
.,O
Lisa,PERSON
H,PERSON
Tostanoski,PERSON
.,O
Lauren,PERSON
Peter,PERSON
.,O
Noe,PERSON
B,PERSON
Mercado,PERSON
.,O
Katherine,PERSON
McMahan,PERSON
.,O
Shant,PERSON
H,O
Mahrokhian,O
.,O
Joseph,PERSON
P,PERSON
Nkolola,PERSON
.,O
Jinyan,PERSON
Liu,PERSON
.,O
Zhenfeng,PERSON
Li,PERSON
.,O
Abishek,PERSON
Chandrashekar,PERSON
.,O
et,O
al,O
.,O
Dna,MISC
vaccine,O
protection,O
against,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
rhesus,O
macaques,O
.,O
Science,O
.,O
2020,DATE
.,O
[,O
26,NUMBER
],O
Benny,PERSON
Borremans,PERSON
.,O
Aman,PERSON
‐,PERSON
dine,O
Gamble,ORGANIZATION
.,O
KC,PERSON
Prager,PERSON
.,O
Sarah,PERSON
K,PERSON
Helman,PERSON
.,O
Abby,PERSON
M,PERSON
McClain,PERSON
.,O
Caitlin,PERSON
Cox,O
.,O
Van,PERSON
Savage,PERSON
.,O
and,O
James,PERSON
O,PERSON
Lloyd,PERSON
‐,PERSON
Smith,PERSON
.,O
Quantifying,O
antibody,O
kinetics,O
and,O
RNA,O
shedding,O
during,O
early,O
‐,O
phase,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infec,O
‐,O
tion,O
.,O
medRxiv,O
.,O
2020,DATE
.,O
[,O
27,NUMBER
],O
Jeroen,PERSON
J.A.,PERSON
van,PERSON
Kampen,PERSON
.,O
David,PERSON
A.M.C.,PERSON
van,PERSON
de,PERSON
Vijver,PERSON
.,O
Pieter,PERSON
L.A.,PERSON
Fraaij,PERSON
.,O
Bart,PERSON
L.,PERSON
Haagmans,PERSON
.,O
Mart,PERSON
M.,PERSON
Lamers,PERSON
.,O
Nisreen,PERSON
Okba,PERSON
.,O
Johannes,PERSON
P.C.,PERSON
van,PERSON
den,PERSON
Akker,PERSON
.,O
Henrik,PERSON
Ende,PERSON
‐,PERSON
man,O
.,O
Diederik,PERSON
A.M.P.J.,PERSON
Gommers,PERSON
.,O
Jan,PERSON
J.,PERSON
Cornelissen,PERSON
.,O
Rogier,PERSON
A.S.,PERSON
Hoek,PERSON
.,O
Menno,PERSON
M.,PERSON
van,PERSON
der,PERSON
Eerden,PERSON
.,O
Dennis,PERSON
A.,PERSON
Hesselink,PERSON
.,O
Herold,PERSON
J.,PERSON
Metselaar,PERSON
.,O
Annelies,PERSON
Verbon,PERSON
.,O
Jurriaan,PERSON
E.M.,PERSON
de,PERSON
Steenwinkel,PERSON
.,O
Georgina,PERSON
I.,PERSON
Aron,PERSON
.,O
Eric,PERSON
C.M.,PERSON
van,PERSON
Gorp,PERSON
.,O
Sander,PERSON
van,PERSON
Boheemen,PERSON
.,O
Jolan,LOCATION
‐,O
da,O
C.,O
Voermans,O
.,O
Charles,PERSON
A.B.,PERSON
Boucher,PERSON
.,O
Richard,PERSON
Molenkamp,PERSON
.,O
Marion,PERSON
P.G.,PERSON
Koopmans,PERSON
.,O
Corine,PERSON
Geurtsvankessel,PERSON
.,O
and,O
Annemiek,PERSON
A.,PERSON
van,PERSON
der,PERSON
Eijk,PERSON
.,O
Shedding,O
of,O
infectious,O
virus,O
in,O
hospitalized,O
patients,O
with,O
coronavirus,O
disease,CAUSE_OF_DEATH
‐,O
2019,DATE
(,O
covid,O
‐,O
19,NUMBER
),O
:,O
duration,O
and,O
key,O
determi,O
‐,O
nants,O
.,O
medRxiv,O
.,O
[,O
28,NUMBER
],O
Hitoshi,PERSON
Kawasuji,PERSON
.,O
Yusuke,PERSON
Takegoshi,PERSON
.,O
Makito,PERSON
Kaneda,ORGANIZATION
.,O
Akitoshi,PERSON
Ueno,PERSON
.,O
Yuki,PERSON
Miyajima,PERSON
.,O
Koyomi,PERSON
Kawago,PERSON
.,O
Yasutaka,PERSON
Fukui,PERSON
.,O
Yoshihiko,PERSON
Yoshida,PERSON
.,O
Miyuki,PERSON
Kimura,PERSON
.,O
Hiroshi,PERSON
Yamada,PERSON
.,O
et,O
al,O
.,O
Viral,O
load,O
dynamics,O
in,O
transmissible,O
symptomatic,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
medRxiv,O
.,O
2020,DATE
.,O
[,O
29,NUMBER
],O
Kelvin,PERSON
Kai,PERSON
‐,O
Wang,O
To,O
.,O
Owen,PERSON
Tak,PERSON
‐,PERSON
Yin,PERSON
Tsang,PERSON
.,O
Wai,PERSON
‐,PERSON
Shing,PERSON
Leung,PERSON
.,O
Anthony,PERSON
Raymond,PERSON
Tam,PERSON
.,O
TakChiu,PERSON
Wu,PERSON
.,O
David,PERSON
Christopher,PERSON
Lung,PERSON
.,O
Cyril,PERSON
Chik,PERSON
‐,PERSON
Yan,PERSON
Yip,PERSON
.,O
Jian,PERSON
‐,PERSON
Piao,PERSON
Cai,PERSON
.,O
Jacky,PERSON
Man,PERSON
‐,PERSON
Chun,PERSON
Chan,PERSON
.,O
Thomas,PERSON
Shiu,PERSON
‐,O
Hong,CITY
Chik,CITY
.,O
et,O
al,O
.,O
Temporal,O
profiles,O
of,O
vi,O
‐,O
ral,O
load,O
in,O
posterior,O
oropharyngeal,O
saliva,O
samples,O
and,O
serum,O
an,O
‐,O
tibody,O
responses,O
during,O
infection,CAUSE_OF_DEATH
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
:,O
an,O
observational,O
cohort,O
study,O
.,O
The,O
Lancet,O
Infectious,O
Diseases,CAUSE_OF_DEATH
.,O
2020,DATE
.,O
[,O
30,NUMBER
],O
Jin,PERSON
Yong,PERSON
Kim,PERSON
.,O
Jae,PERSON
‐,PERSON
Hoon,PERSON
Ko,PERSON
.,O
Yeonjae,PERSON
Kim,PERSON
.,O
Yae,O
‐,O
Jean,PERSON
Kim,PERSON
.,O
Jeong,PERSON
‐,PERSON
Min,PERSON
Kim,PERSON
.,O
Yoon,PERSON
‐,PERSON
Seok,PERSON
Chung,PERSON
.,O
Heui,PERSON
Man,PERSON
Kim,PERSON
.,O
Myung,O
‐,O
Guk,O
Han,O
.,O
So,O
Yeon,PERSON
Kim,PERSON
.,O
and,O
Bum,PERSON
Sik,PERSON
Chin,PERSON
.,O
Viral,O
load,O
[,O
31,NUMBER
],O
Ai,O
Tang,PERSON
Xiao,PERSON
.,O
Yi,PERSON
Xin,PERSON
Tong,PERSON
.,O
and,O
Sheng,PERSON
Zhang,PERSON
.,O
Profile,O
of,O
RT,O
‐,O
PCR,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
:,O
a,O
preliminary,O
study,O
from,O
56,NUMBER
COVID,O
‐,O
19,NUMBER
patients,O
.,O
Clinical,O
Infectious,O
Diseases,CAUSE_OF_DEATH
.,O
2020,DATE
.,O
[,O
32,NUMBER
],O
Yang,PERSON
Liu,PERSON
.,O
Li,PERSON
‐,PERSON
Meng,PERSON
Yan,PERSON
.,O
Lagen,PERSON
Wan,PERSON
.,O
Tian,PERSON
‐,PERSON
Xin,PERSON
Xiang,PERSON
.,O
Aiping,PERSON
Le,PERSON
.,O
Jia,PERSON
‐,PERSON
Ming,PERSON
Liu,PERSON
.,O
Malik,PERSON
Peiris,PERSON
.,O
Leo,PERSON
LM,PERSON
Poon,PERSON
.,O
and,O
Wei,PERSON
Zhang,PERSON
.,O
Viral,O
dynamics,O
in,O
mild,O
and,O
severe,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
The,O
Lancet,O
Infectious,O
Diseases,CAUSE_OF_DEATH
.,O
2020,DATE
.,O
[,O
33,NUMBER
],O
Minnesota,STATE_OR_PROVINCE
Population,O
Cen,O
‐,O
ter,TITLE
.,O
Integrated,O
public,O
use,O
microdata,O
series,O
.,O
international,O
:,O
Ver,O
‐,O
sion,O
[,O
34,NUMBER
],O
Yang,PERSON
Liu,PERSON
.,O
Rosalind,PERSON
Eggo,PERSON
.,O
and,O
Adam,PERSON
Kucharski,PERSON
.,O
Secondary,O
attack,CAUSE_OF_DEATH
rate,O
and,O
superspreading,O
events,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
The,O
Lancet,O
.,O
2020,DATE
.,O
[,O
35,NUMBER
],O
Kiesha,PERSON
Prem,PERSON
.,O
Alex,PERSON
Cook,PERSON
.,O
and,O
Mark,PERSON
Jit,PERSON
.,O
Projecting,O
so,O
‐,O
cial,O
contact,O
matrices,O
in,O
152,NUMBER
countries,O
using,O
contact,O
surveys,O
and,O
demographic,O
data,O
.,O
PLoS,O
Computational,O
Biology,O
.,O
13,NUMBER
(,O
9,NUMBER
),O
:,O
e1005697,O
.,O
no,O
surveillance,O
test,O
‐,O
based,O
isolation,O
symptom,O
‐,O
based,O
isolation,O
LOD,O
103,NUMBER
.,O
every,SET
7,SET
days,SET
LOD,O
105,NUMBER
.,O
every,SET
7,SET
days,SET
LOD,O
105,NUMBER
.,O
every,SET
3,SET
days,SET
number,O
of,O
infected,O
individuals,O
in,O
a,O
population,O
of,O
N,O
=,O
20,NUMBER
.,O
000,NUMBER
with,O
a,O
constant,O
rate,O
of,O
external,O
infection,CAUSE_OF_DEATH
set,O
to,O
1,NUMBER
/,O
N,O
per,O
person,O
per,O
day,DURATION
.,O
i.e.,O
around,O
1,NUMBER
imported,O
case,O
per,O
day,DURATION
.,O
Infections,CAUSE_OF_DEATH
(,O
blue,O
),O
.,O
test,O
‐,O
based,O
isolation,O
(,O
black,O
),O
.,O
and,O
symptom,O
‐,O
based,O
isolation,O
(,O
red,O
),O
are,O
shown,O
for,O
four,NUMBER
scenarios,O
.,O
with,O
R0,O
=,O
2.5,NUMBER
.,O
(,O
A,O
),O
No,O
surveillance,O
.,O
(,O
B,O
),O
Weekly,SET
testing,O
at,O
LOD,O
103,NUMBER
.,O
(,O
C,O
),O
Weekly,SET
testing,O
at,O
LOD,O
105,NUMBER
.,O
(,O
D,O
),O
Testing,O
every,SET
3,SET
days,SET
with,O
LOD,O
105,NUMBER
.,O
Note,O
the,O
variation,O
in,O
the,O
vertical,O
axis,O
scales,O
.,O
The,O
model,TITLE
is,O
fully,O
described,O
in,O
Methods,O
.,O
fully,O
mixed,O
model,TITLE
effective,O
repr,O
.,O
num,O
.,O
R,O
total,O
infections,CAUSE_OF_DEATH
days,DURATION
between,O
tests,O
agent,O
based,O
model,TITLE
effective,O
repr,O
.,O
num,O
.,O
R,O
total,O
in,O
‐,O
fections,O
fully,O
mixed,O
model,TITLE
days,DURATION
between,O
tests,O
agent,O
based,O
model,TITLE
days,DURATION
between,O
tests,O
days,DURATION
between,O
tests,O
model,TITLE
(,O
top,O
row,O
),O
and,O
agent,O
based,O
model,TITLE
(,O
bottom,O
row,O
),O
were,O
simulated,O
(,O
Methods,O
),O
with,O
various,O
test,O
frequencies,O
.,O
ranging,O
from,O
daily,SET
to,O
once,DATE
every,SET
14,SET
days,SET
.,O
and,O
with,O
LODs,O
of,O
103,NUMBER
.,O
105,NUMBER
.,O
and,NUMBER
106,NUMBER
.,O
Modeling,O
results,O
show,O
mean,O
outcomes,O
from,O
50,NUMBER
independent,RELIGION
simulations,O
at,O
each,O
point,O
.,O
expressed,O
as,O
(,O
A,O
.,O
B,O
),O
total,O
infections,CAUSE_OF_DEATH
and,O
(,O
C,O
.,O
D,O
),O
effective,O
reproductive,O
num,O
‐,O
ber,O
R,O
.,O
from,O
a,O
baseline,O
of,O
R0,O
=,O
2.5,NUMBER
.,O
For,O
the,O
fully,O
mixed,O
model,TITLE
.,O
only,O
secondary,O
infections,CAUSE_OF_DEATH
are,O
shown,O
.,O
excluding,O
imported,O
infec,O
‐,O
tions,O
.,O
Total,O
population,O
sizes,O
were,O
N,O
=,O
2,NUMBER
104,NUMBER
for,O
the,O
fully,O
mixed,O
model,TITLE
and,O
8.4,NUMBER
106,NUMBER
for,O
the,O
agent,O
based,O
model,TITLE
.,O
Dashed,O
lines,O
indi,O
‐,O
cate,O
R,O
=,O
1,NUMBER
for,O
reference,O
.,O
reduction,O
in,O
R,O
agent,O
based,O
model,TITLE
total,O
infections,CAUSE_OF_DEATH
fully,O
mixed,O
model,TITLE
dx,O
delay,O
no,O
test,O
daily,SET
total,O
infec,O
‐,O
tions,O
agent,O
based,O
model,TITLE
reduction,O
in,O
R,O
fully,O
mixed,O
model,TITLE
no,O
test,O
daily,SET
viral,O
load,O
.,O
Compare,O
with,O
threshold,O
(,O
binary,O
),O
infectiousness,O
in,O
Fig,O
.,O
S4,O
and,O
log,O
‐,O
proportional,O
infectiousness,O
in,O
Fig,O
4,NUMBER
.,O
See,O
Methods,O
.,O
reduction,O
in,O
R,O
agent,O
based,O
model,TITLE
total,O
infections,CAUSE_OF_DEATH
fully,O
mixed,O
model,TITLE
dx,O
delay,O
no,O
test,O
daily,SET
total,O
infections,CAUSE_OF_DEATH
agent,O
based,O
model,TITLE
reduction,O
in,O
R,O
fully,O
mixed,O
model,TITLE
no,O
test,O
daily,SET
below,O
106,NUMBER
and,O
equal,O
infectiousness,O
for,O
any,O
viral,O
load,O
above,O
106,NUMBER
.,O
Compare,O
with,O
proportional,O
infectiousness,O
in,O
Fig,O
.,O
S3,O
and,O
log,O
‐,O
proportional,O
infectiousness,O
in,O
Fig,O
4,NUMBER
.,O
See,O
Methods,O
.,O
fully,O
mixed,O
model,TITLE
logpro,O
‐,O
portional,O
infectiousness,O
agent,O
based,O
model,TITLE
logproportional,O
infec,O
‐,O
tiousness,O
fully,O
mixed,O
model,TITLE
proportional,O
infectiousness,O
total,O
in,O
‐,O
fections,O
total,O
infections,CAUSE_OF_DEATH
agent,O
based,O
model,TITLE
proportional,O
infec,O
‐,O
tiousness,O
total,O
infections,CAUSE_OF_DEATH
fully,O
mixed,O
model,TITLE
threshold,O
infec,O
‐,O
tiousness,O
days,DURATION
between,O
tests,O
0,DURATION
day,DURATION
delay,O
fully,O
mixed,O
model,TITLE
pro,O
‐,O
portional,O
infectiousness,O
days,DURATION
between,O
tests,O
agent,O
based,O
model,TITLE
proportional,O
infectiousness,O
days,DURATION
between,O
tests,O
0,DURATION
day,DURATION
delay,O
fully,O
mixed,O
model,TITLE
threshold,O
infectiousness,O
days,DURATION
between,O
tests,O
days,DURATION
be,O
‐,O
tween,O
tests,O
days,DURATION
between,O
tests,O
total,O
infections,CAUSE_OF_DEATH
agent,O
based,O
model,TITLE
threshold,O
infectiousness,O
days,DURATION
between,O
tests,O
agent,O
based,O
model,TITLE
logproportional,O
infectiousness,O
days,DURATION
between,O
tests,O
days,DURATION
between,O
tests,O
fully,O
mixed,O
model,TITLE
logproportional,O
infectiousness,O
days,DURATION
be,O
‐,O
tween,O
tests,O
effective,O
repr,O
.,O
num,O
.,O
R,O
total,O
infections,CAUSE_OF_DEATH
effective,O
repr,O
.,O
num,O
.,O
R,O
0,DURATION
day,DURATION
delay,O
days,DURATION
between,O
tests,O
effective,O
repr,O
.,O
num,O
.,O
R,O
effective,O
repr,O
.,O
num,O
.,O
R,O
total,O
infections,CAUSE_OF_DEATH
effective,O
repr,O
.,O
num,O
.,O
R,O
days,DURATION
between,O
tests,O
effective,O
repr,O
.,O
num,O
.,O
R,O
agent,O
based,O
model,TITLE
threshold,O
infectiousness,O
with,O
various,O
test,O
frequencies,O
.,O
ranging,O
from,O
daily,SET
to,O
once,DATE
every,SET
14,SET
days,SET
.,O
with,O
LODs,O
of,O
103,NUMBER
.,O
105,NUMBER
.,O
and,O
106,NUMBER
.,O
and,O
with,O
delays,O
of,O
0,NUMBER
.,O
1,NUMBER
.,O
2,NUMBER
.,O
or,O
3,DURATION
days,DURATION
.,O
for,O
log,O
‐,O
proportion,O
‐,O
al,O
.,O
proportional,O
.,O
and,O
threshold,O
infectiousness,O
functions,O
(,O
see,O
Methods,O
),O
.,O
Legends,O
in,O
panels,O
A,O
and,O
B,O
indicate,O
LODs,O
and,O
delays,O
.,O
and,O
in,O
‐,O
plot,O
annotations,O
describe,O
various,O
conditions,O
.,O
Modeling,O
results,O
show,O
mean,O
outcomes,O
from,O
50,NUMBER
independent,RELIGION
simulations,O
at,O
each,O
point,O
.,O
expressed,O
as,O
total,O
infections,CAUSE_OF_DEATH
and,O
effective,O
reproductive,O
number,O
R,O
.,O
from,O
a,O
baseline,O
of,O
R0,O
=,O
2.5,NUMBER
.,O
For,O
the,O
fully,O
mixed,O
model,TITLE
.,O
only,O
secondary,O
infections,CAUSE_OF_DEATH
are,O
shown,O
.,O
excluding,O
imported,O
infections,CAUSE_OF_DEATH
.,O
Total,O
population,O
sizes,O
were,O
N,O
=,O
2,NUMBER
104,NUMBER
for,O
the,O
fully,O
mixed,O
model,TITLE
and,O
8.4,NUMBER
106,NUMBER
for,O
the,O
agent,O
based,O
model,TITLE
.,O
Dashed,O
lines,O
indicate,O
R,O
=,O
1,NUMBER
for,O
reference,O
.,O
total,O
infections,CAUSE_OF_DEATH
fully,O
mixed,O
model,TITLE
no,O
test,O
to,O
‐,O
tal,O
infections,CAUSE_OF_DEATH
fully,O
mixed,O
model,TITLE
no,O
dx,O
delay,O
1,DURATION
day,DURATION
delay,O
2,DURATION
day,DURATION
delay,O
total,O
infections,CAUSE_OF_DEATH
agent,O
based,O
model,TITLE
no,O
test,O
daily,SET
no,O
test,O
daily,SET
from,O
the,O
fully,O
‐,O
mixed,O
simulation,O
with,O
a,O
tripled,O
rate,O
of,O
ex,O
‐,O
ternal,O
infection,CAUSE_OF_DEATH
.,O
i.e.,O
3,NUMBER
/,O
N,O
per,O
person,O
per,O
day,DURATION
.,O
(,O
B,O
),O
Results,O
from,O
the,O
fully,O
mixed,O
simulation,O
with,O
R0,O
doubled,O
.,O
i.e.,O
R0,O
=,O
5,NUMBER
.,O
(,O
C,O
),O
Re,O
‐,O
sults,O
from,O
the,O
agent,O
‐,O
based,O
simulation,O
with,O
R0,O
doubled,O
.,O
i.e.,O
R0,O
=,O
5,NUMBER
.,O
Viral,O
Loads,O
Viral,O
loads,O
were,O
drawn,O
from,O
a,O
simple,O
viral,O
kinet,O
‐,O
ics,O
model,TITLE
intended,O
to,O
capture,O
(,O
1,NUMBER
),O
a,O
variable,O
latent,O
period,O
.,O
(,O
2,NUMBER
),O
a,O
rapid,O
growth,O
phase,O
from,O
the,O
lower,O
limit,O
of,O
PCR,O
detectability,O
to,O
a,O
peak,O
viral,O
load,O
.,O
and,O
(,O
3,NUMBER
),O
a,O
slower,O
decay,O
phase,O
.,O
These,O
dynamics,O
were,O
based,O
on,O
the,O
following,O
observations,O
.,O
Latent,O
periods,O
prior,O
to,O
symptoms,O
have,O
been,O
estimated,O
to,O
be,O
around,O
5,DURATION
day,DURATION
[,O
23,NUMBER
],O
.,O
Viral,O
load,O
appears,O
to,O
peak,O
prior,O
to,O
symptom,O
onset,O
[,O
4,NUMBER
],O
.,O
and,O
peaks,O
within,O
2,DURATION
days,DURATION
of,O
challenge,O
in,O
a,O
macaque,O
model,TITLE
[,O
24,NUMBER
.,O
25,NUMBER
],O
.,O
though,O
it,O
should,O
be,O
noted,O
that,O
macaque,O
challenge,O
doses,O
were,O
high,O
.,O
Viral,O
load,O
de,O
‐,O
creases,O
3,NUMBER
or,O
more,O
days,DURATION
before,O
symptom,O
onset,O
[,O
1,NUMBER
.,O
30,NUMBER
],O
.,O
Peak,O
viral,O
loads,O
are,O
difficult,O
to,O
measure,O
due,O
to,O
lack,O
of,O
prospective,O
sam,O
‐,O
pling,O
studies,O
of,O
individuals,O
prior,O
to,O
exposure,O
and,O
infection,CAUSE_OF_DEATH
.,O
but,O
viral,O
loads,O
have,O
been,O
reported,O
in,O
the,O
range,O
of,O
O,O
(,O
104,NUMBER
),O
to,O
O,O
(,O
109,NUMBER
),O
copies,O
per,O
ml,O
[,O
8,NUMBER
.,O
28,NUMBER
.,O
29,NUMBER
],O
.,O
Viral,O
loads,O
appear,O
to,O
timing,O
may,O
dif,O
‐,O
fer,O
depending,O
on,O
the,O
degree,O
or,O
presence,O
of,O
symptoms,O
[,O
31,NUMBER
.,O
32,NUMBER
],O
.,O
Fi,O
‐,O
nally,O
.,O
we,O
note,O
that,O
the,O
general,TITLE
understanding,O
of,O
viral,O
kinetics,O
may,O
vary,O
depending,O
on,O
the,O
mode,O
of,O
sampling,O
.,O
as,O
demonstrated,O
via,O
a,O
comparison,O
between,O
sputum,O
and,O
swab,O
samples,O
[,O
8,NUMBER
],O
.,O
To,O
mimic,O
growth,O
and,O
decay,O
.,O
log10,O
viral,O
loads,O
were,O
specified,O
by,O
a,O
continuous,O
piecewise,O
linear,O
crosses,O
103,NUMBER
.,O
with,O
t0,O
unif,O
[,O
2.5,NUMBER
.,O
3.5,NUMBER
],O
.,O
measured,O
in,O
days,DURATION
since,O
exposure,O
.,O
The,O
second,ORDINAL
point,O
represents,O
the,O
peak,O
vi,O
‐,O
ral,O
load,O
.,O
Peak,O
height,O
was,O
drawn,O
Vpeak,O
unif,O
[,O
7,NUMBER
.,O
11,NUMBER
],O
.,O
and,O
peak,O
tim,O
‐,O
ing,O
was,O
drawn,O
with,O
respect,O
to,O
the,O
start,O
of,O
the,O
exponential,O
growth,O
phase,O
.,O
tpeak,O
t0,O
0.2,NUMBER
+,O
gamma,O
(,O
1.8,NUMBER
),O
.,O
The,O
third,ORDINAL
point,O
represents,O
the,O
time,O
at,O
which,O
an,O
individuals,O
viral,O
load,O
crosses,O
beneath,O
the,O
106,NUMBER
threshold,O
.,O
at,O
which,O
point,O
viral,O
loads,O
no,O
longer,O
cause,O
active,O
cultures,O
in,O
laboratory,O
experiments,O
[,O
7,NUMBER
.,O
8,NUMBER
.,O
9,NUMBER
],O
.,O
and,O
was,O
drawn,O
with,O
respect,O
to,O
peak,O
timing,O
.,O
tf,O
tpeak,O
unif,O
[,O
5,NUMBER
.,O
10,NUMBER
],O
.,O
In,O
simulations,O
.,O
each,O
viral,O
loads,O
parameters,O
were,O
drawn,O
independently,O
of,O
others,O
.,O
and,O
the,O
continuous,O
function,O
described,O
here,O
was,O
evaluated,O
at,O
In,O
‐,O
fectiousness,O
F,O
was,O
assumed,O
to,O
be,O
directly,O
related,O
to,O
viral,O
load,O
V,O
in,O
one,NUMBER
of,O
three,NUMBER
ways,O
.,O
In,O
the,O
main,O
text,O
.,O
each,O
individuals,O
relative,O
infectiousness,O
was,O
proportional,O
log10,O
of,O
viral,O
loads,O
excess,O
be,O
‐,O
yond,O
106,NUMBER
.,O
i.e.,O
F,O
log10,O
(,O
V,O
),O
6,NUMBER
.,O
In,O
the,O
supplementary,O
sensitivi,O
‐,O
ty,O
analyses,O
.,O
we,O
investigated,O
two,NUMBER
opposing,O
extremes,O
.,O
To,O
capture,O
a,O
more,O
extreme,O
relationship,O
between,O
infectiousness,O
and,O
viral,O
load,O
.,O
we,O
considered,O
F,O
to,O
be,O
directly,O
proportional,O
to,O
viral,O
loads,O
excess,O
above,O
106,NUMBER
.,O
i.e.,O
F,O
10log10,O
(,O
V,O
),O
6,NUMBER
=,O
V,NUMBER
106,NUMBER
.,O
and,O
to,O
capture,O
a,O
more,O
extreme,O
relationship,O
.,O
but,O
in,O
the,O
opposing,O
direction,O
.,O
we,O
consid,O
‐,O
ered,O
F,O
to,O
simply,O
be,O
a,O
constant,O
when,O
viral,O
load,O
exceeded,O
106,NUMBER
.,O
i.e.,O
F,O
1V,O
>,O
106,NUMBER
.,O
We,O
call,O
these,O
three,NUMBER
functions,O
log,O
‐,O
proportional,O
.,O
proportional,O
.,O
and,O
threshold,O
throughout,O
the,O
text,O
and,O
log10,O
viral,O
load,O
(,O
virions,O
/,O
mL,O
),O
viral,O
load,O
viral,O
load,O
(,O
discrete,O
time,O
),O
control,O
points,O
days,DURATION
since,O
exposure,O
.,O
t,O
sampled,O
.,O
Light,O
grey,O
lines,O
show,O
20,NUMBER
alternative,O
trajectories,O
to,O
illustrate,O
the,O
diversity,O
of,O
viral,O
loads,O
drawn,O
from,O
the,O
simple,O
model,TITLE
.,O
supplemental,O
materials,O
.,O
our,O
infectiousness,O
functions,O
.,O
this,O
inferred,O
relationship,O
bears,O
the,O
greatest,O
similarity,O
.,O
over,O
time,O
.,O
to,O
the,O
log,O
‐,O
proportional,O
infec,O
‐,O
tiousness,O
function,O
.,O
as,O
visualized,O
in,O
Figs.,O
1,NUMBER
and,O
3,NUMBER
.,O
The,O
propor,O
‐,O
tional,O
and,O
threshold,O
models,O
therefore,O
represent,O
one,NUMBER
of,O
many,O
types,O
of,O
sensitivity,O
analysis,O
.,O
Results,O
for,O
those,O
In,O
all,O
simulations,O
.,O
the,O
value,O
of,O
the,O
proportionality,O
constant,O
implied,O
by,O
the,O
infec,O
‐,O
tiousness,O
functions,O
above,O
was,O
chosen,O
to,O
achieve,O
the,O
targeted,O
val,O
‐,O
ue,O
of,O
R0,O
for,O
that,O
simulation,O
.,O
and,O
confirmed,O
via,O
simulation,O
as,O
de,O
‐,O
scribed,O
below,O
.,O
Disease,CAUSE_OF_DEATH
Transmission,MISC
Models,MISC
Two,NUMBER
models,O
were,O
used,O
to,O
simulate,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
dynamics,O
.,O
both,O
based,O
on,O
a,O
typical,O
compart,O
‐,O
mental,O
framework,O
.,O
The,O
first,ORDINAL
model,TITLE
was,O
a,O
fully,O
‐,O
mixed,O
model,TITLE
of,O
N,O
=,O
20,NUMBER
.,O
000,NUMBER
individuals,O
with,O
all,O
‐,O
to,O
‐,O
all,O
contact,O
structure,O
.,O
zero,NUMBER
ini,O
‐,O
tial,O
infections,CAUSE_OF_DEATH
.,O
and,O
a,O
constant,O
1,NUMBER
/,O
N,O
per,O
‐,O
person,O
probability,O
of,O
be,O
‐,O
coming,O
infected,O
from,O
an,O
external,O
source,O
.,O
This,O
model,TITLE
could,O
repre,O
‐,O
sent,O
.,O
for,O
instance,O
.,O
a,O
large,O
college,O
campus,O
with,O
high,O
mixing,O
.,O
sit,O
‐,O
uated,O
within,O
a,O
larger,O
community,O
with,O
low,O
‐,O
level,O
disease,CAUSE_OF_DEATH
preva,O
‐,O
lence,O
.,O
The,O
second,ORDINAL
model,TITLE
was,O
an,O
agent,O
‐,O
based,O
model,TITLE
of,O
N,O
=,O
8.4,NUMBER
mil,O
‐,O
lion,O
agents,O
representing,O
the,O
population,O
and,O
contact,O
structure,O
of,O
New,CITY
York,CITY
City,CITY
.,O
as,O
previously,DATE
described,O
[,O
18,NUMBER
],O
.,O
Contact,O
patterns,O
were,O
based,O
on,O
a,O
combination,O
of,O
individual,O
‐,O
level,O
household,O
con,O
‐,O
tacts,O
drawn,O
from,O
census,O
microdata,O
and,O
agestratified,O
contact,O
ma,O
‐,O
trices,O
which,O
describe,O
outside,O
of,O
household,O
contacts,O
.,O
This,O
model,TITLE
was,O
initialized,O
with,O
100,NUMBER
initial,O
infections,CAUSE_OF_DEATH
and,O
no,O
external,O
sources,O
of,O
infection,CAUSE_OF_DEATH
.,O
Both,O
the,O
fully,O
‐,O
mixed,O
and,O
agent,O
‐,O
based,O
mod,O
‐,O
els,O
tracked,O
discrete,O
individuals,O
who,O
were,O
Susceptible,O
(,O
S,O
),O
.,O
In,O
‐,O
fected,O
(,O
I,O
),O
.,O
Recovered,O
(,O
R,O
),O
.,O
Isolated,O
(,O
Q,O
),O
.,O
and,O
Self,O
‐,O
Isolated,O
(,O
SQ,O
),O
at,O
each,O
discrete,O
one,DURATION
day,DURATION
timestep,O
.,O
Upon,O
becoming,O
infected,O
(,O
S,O
I,O
),O
.,O
a,O
viral,O
load,O
trajectory,O
V,O
(,O
t,O
),O
was,O
drawn,O
which,O
included,O
a,O
latent,O
period,O
.,O
growth,O
.,O
and,O
decay,O
.,O
Each,SET
day,SET
.,O
an,O
individuals,O
viral,O
load,O
trajectory,O
was,O
used,O
to,O
determine,O
whether,O
their,O
diagnostic,O
test,O
would,O
be,O
positive,O
if,O
administered,O
.,O
as,O
well,O
as,O
their,O
infectious,O
‐,O
ness,O
to,O
susceptible,O
individuals,O
.,O
Based,O
on,O
a,O
schedule,O
of,O
testing,O
each,O
person,O
every,O
D,O
days,DURATION
.,O
if,O
an,O
individual,O
happened,O
to,O
be,O
tested,O
on,O
a,DURATION
day,DURATION
when,O
their,O
viral,O
load,O
exceeded,O
the,O
limit,O
of,O
detection,O
L,O
of,O
the,O
test,O
.,O
their,O
positive,O
result,O
would,O
cause,O
them,O
to,O
isolate,O
(,O
I,O
Q,O
),O
.,O
but,O
with,O
the,O
possibility,O
of,O
a,O
delay,O
in,O
turnaround,O
time,O
.,O
A,O
fraction,O
1,NUMBER
f,O
of,O
individuals,O
self,O
‐,O
isolate,O
on,O
the,DURATION
first,DURATION
day,DURATION
after,O
peak,O
viral,O
load,O
.,O
to,O
mimic,O
symptom,O
‐,O
driven,O
isolation,O
(,O
I,O
SQ,O
),O
.,O
with,O
f,O
=,O
0.8,NUMBER
for,O
the,O
fully,O
mixed,O
model,TITLE
and,O
f,O
=,O
1,NUMBER
for,O
the,O
agent,O
based,O
model,TITLE
.,O
When,O
an,O
individuals,O
viral,O
load,O
dropped,O
below,O
103,NUMBER
.,O
that,O
individual,O
recovered,O
(,O
I,O
.,O
Q,O
.,O
SQ,O
R,O
),O
.,O
Details,O
follow,O
.,O
Testing,O
.,O
Isolation,O
.,O
and,O
Sample,O
‐,O
to,O
‐,O
Answer,O
Turnaround,O
Times,O
All,O
individuals,O
were,O
tested,O
every,O
D,O
days,DURATION
.,O
so,O
that,O
they,O
could,O
be,O
moved,O
into,O
isola,O
‐,O
tion,O
if,O
their,O
viral,O
load,O
exceeded,O
the,O
tests,O
limit,O
of,O
detection,O
V,O
(,O
t,O
),O
>,O
L.,O
Each,O
person,O
was,O
deterministically,O
tested,O
exactly,O
every,O
D,O
days,DURATION
.,O
but,O
testing,O
days,DURATION
were,O
drawn,O
uniformly,O
at,O
random,O
such,O
that,O
not,O
all,O
individuals,O
were,O
tested,O
on,O
the,DATE
same,DATE
day,DATE
.,O
To,O
account,O
for,O
delays,O
in,O
returning,O
test,O
results,O
.,O
we,O
included,O
a,O
sample,O
‐,O
to,O
‐,O
answer,O
turnaround,O
time,O
T,O
.,O
meaning,O
that,O
an,O
individual,O
with,O
a,O
positive,O
test,O
on,O
day,DURATION
t,O
would,O
isolate,O
on,O
day,DURATION
t,O
+,O
T,O
.,O
Transmission,O
.,O
Popula,PERSON
‐,PERSON
tion,O
Structure,O
.,O
and,O
Mixing,O
Patterns,O
:,O
Fully,O
‐,O
mixed,O
model,TITLE
Simula,O
‐,O
tions,O
were,O
initialized,O
with,O
all,O
individuals,O
susceptible,O
.,O
S,O
=,O
N,O
.,O
Each,O
individual,O
was,O
chosen,O
to,O
be,O
symptomatic,O
independently,O
with,O
probability,O
f,O
.,O
and,O
each,O
individuals,O
first,ORDINAL
test,O
day,DURATION
(,O
e.g.,O
the,DATE
day,DATE
of,O
the,DATE
week,DATE
that,O
their,O
weekly,SET
test,O
would,O
occur,O
),O
was,O
chosen,O
uni,O
‐,O
formly,O
at,O
random,O
between,O
1,NUMBER
and,O
D.,O
Relative,O
infectiousness,O
was,O
scaled,O
up,O
or,O
down,O
to,O
achieve,O
the,O
specified,O
R0,O
in,O
the,O
absence,O
of,O
any,O
testing,O
policy,O
.,O
but,O
inclusive,O
of,O
any,O
assumed,O
self,O
‐,O
isolation,O
of,O
symptomatics,O
.,O
In,O
each,O
timestep,O
.,O
those,O
individuals,O
who,O
were,O
marked,O
for,O
testing,O
that,O
day,DURATION
were,O
tested,O
.,O
and,O
a,O
counter,O
was,O
ini,O
‐,O
tialized,O
to,O
T,O
.,O
specifying,O
the,O
number,O
of,O
days,DURATION
until,O
that,O
individ,O
‐,O
ual,O
received,O
their,O
results,O
.,O
Next,O
.,O
individuals,O
whose,O
test,O
results,O
counters,O
were,O
zero,NUMBER
were,O
isolated,O
.,O
I,O
Q.,O
Then,O
.,O
symptomatic,O
indi,O
‐,O
viduals,O
whose,O
viral,O
load,O
had,O
declined,O
relative,O
to,O
the,O
previous,O
day,DURATION
were,O
self,O
‐,O
isolated,O
.,O
I,O
SQ,O
.,O
Next,O
.,O
each,O
susceptible,O
individual,O
was,O
spontaneously,O
(,O
externally,O
),O
infected,O
independently,O
with,O
proba,O
‐,O
bility,O
1,NUMBER
/,O
N,O
.,O
S,O
I.,O
Then,O
.,O
all,O
infected,O
individuals,O
contacted,O
all,O
susceptible,O
individuals,O
.,O
with,O
the,O
probability,O
of,O
transmission,O
based,O
on,O
that,O
days,DURATION
viral,O
load,O
V,O
(,O
t,O
),O
for,O
each,O
person,O
and,O
the,O
par,O
‐,O
ticular,O
infectiousness,O
function,O
.,O
described,O
above,O
.,O
S,O
I.,O
To,O
con,O
‐,O
clude,O
each,O
time,O
step,O
.,O
individuals,O
viral,O
loads,O
and,O
test,O
results,O
counters,O
were,O
advanced,O
.,O
with,O
those,O
whose,O
infectious,O
period,O
had,O
completely,O
passed,O
moved,O
to,O
recovery,O
.,O
I,O
.,O
Q,O
.,O
SQ,O
R.,O
Transmission,O
.,O
Population,O
Structure,O
.,O
and,O
Mixing,O
Patterns,O
:,O
Agent,O
‐,O
based,O
model,TITLE
The,O
agent,O
‐,O
based,O
model,TITLE
added,O
viral,O
kinetics,O
and,O
testing,O
policies,O
(,O
as,O
described,O
above,O
),O
to,O
an,O
existing,O
model,TITLE
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
transmission,O
in,O
New,CITY
York,CITY
City,CITY
.,O
A,O
full,O
description,O
of,O
the,O
agent,O
‐,O
based,O
model,TITLE
is,O
available,O
[,O
18,NUMBER
],O
;,O
here,O
we,O
provide,O
an,O
overview,O
of,O
the,O
relevant,O
transmission,O
dynamics,O
.,O
Simulations,O
were,O
initialized,O
with,O
all,O
in,O
‐,O
dividuals,O
susceptible,O
.,O
except,O
for,O
100,NUMBER
initially,O
infected,O
individ,O
‐,O
uals,O
.,O
S,O
=,O
N,O
100,NUMBER
.,O
As,O
in,O
the,O
fully,O
‐,O
mixed,O
model,TITLE
.,O
each,O
individuals,O
test,O
day,DURATION
was,O
chosen,O
uniformly,O
at,O
random,O
and,O
relative,O
infectious,O
‐,O
ness,O
was,O
scaled,O
to,O
achieve,O
the,O
specified,O
R0,O
.,O
In,O
each,O
timestep,O
.,O
those,O
individuals,O
who,O
were,O
marked,O
for,O
testing,O
that,O
day,DURATION
were,O
test,O
‐,O
ed,O
.,O
and,O
a,O
counter,O
was,O
initialized,O
to,O
T,O
.,O
specifying,O
the,O
number,O
of,O
days,DURATION
until,O
that,O
individual,O
received,O
their,O
results,O
.,O
Next,O
.,O
indi,O
‐,O
viduals,O
whose,O
test,O
results,O
counters,O
were,O
zero,NUMBER
were,O
isolated,O
.,O
I,O
Q,O
.,O
There,O
was,O
no,O
selfisolation,O
in,O
this,O
model,TITLE
(,O
and,O
accordingly,O
.,O
the,O
model,TITLE
did,O
not,O
label,O
individuals,O
as,O
symptomatic,O
or,O
Then,O
.,O
transmis,O
‐,O
sion,O
from,O
infected,O
individuals,O
to,O
susceptible,O
individuals,O
was,O
simulated,O
both,O
within,O
and,O
outside,O
households,O
.,O
To,O
model,O
within,O
‐,O
household,O
transmission,O
.,O
each,O
individual,O
had,O
a,O
set,O
of,O
other,O
indi,O
‐,O
viduals,O
comprising,O
their,O
household,O
.,O
Household,O
structures,O
.,O
along,O
with,O
the,O
age,O
of,O
each,O
individual,O
.,O
were,O
sampled,O
from,O
census,O
micro,O
‐,O
data,O
for,O
New,CITY
York,CITY
City,CITY
[,O
33,NUMBER
],O
.,O
The,O
probability,O
for,O
an,O
infectious,O
individual,O
to,O
infect,O
each,O
of,O
their,O
household,O
members,O
each,SET
day,SET
was,O
determined,O
by,O
scaling,O
the,O
relative,O
infectiousness,O
values,O
to,O
match,O
the,O
estimated,O
secondary,O
attack,CAUSE_OF_DEATH
rate,O
for,O
close,O
household,O
contacts,O
previously,DATE
reported,O
in,O
case,O
cluster,O
studies,O
[,O
34,NUMBER
],O
.,O
Outside,O
of,O
household,O
transmission,O
was,O
simulated,O
using,O
age,O
‐,O
stratified,O
contact,O
matrices,O
.,O
which,O
describe,O
the,O
expected,O
number,O
of,O
daily,SET
contacts,O
between,O
an,O
individual,O
in,O
a,O
given,O
age,O
group,O
and,O
those,O
in,O
each,O
oth,O
‐,O
er,O
age,O
group,O
.,O
Each,O
infectious,O
individual,O
of,O
age,O
i,O
drew,O
Pois,O
‐,O
son,O
(,O
Mij,O
),O
contacts,O
with,O
individuals,O
in,O
age,O
group,O
j,O
.,O
where,O
M,O
is,O
the,O
contact,O
matrix,O
.,O
The,O
contacted,O
individuals,O
were,O
sampled,O
uni,O
‐,O
formly,O
at,O
random,O
from,O
age,O
group,O
j,O
.,O
We,O
use,O
a,O
contact,O
matrix,O
for,O
the,O
United,COUNTRY
States,COUNTRY
estimated,O
by,O
[,O
35,NUMBER
],O
.,O
Each,O
contact,O
resulted,O
in,O
in,O
‐,O
fection,O
.,O
S,O
I,O
.,O
with,O
probability,O
proportional,O
to,O
the,O
relative,O
in,O
‐,O
fectiousness,O
of,O
the,O
infected,O
individual,O
on,O
that,O
day,DURATION
.,O
scaled,O
to,O
obtain,O
the,O
specified,O
value,O
of,O
R0,O
.,O
To,O
conclude,O
each,O
time,O
step,O
.,O
individuals,O
viral,O
loads,O
and,O
test,O
results,O
counters,O
were,O
advanced,O
.,O
with,O
those,O
whose,O
infectious,O
period,O
had,O
completely,O
passed,O
moved,O
to,O
recovery,O
.,O
I,O
.,O
Q,O
R.,O
Calibration,O
to,O
achieve,O
targeted,O
R0,O
and,O
esti,O
‐,O
mation,O
of,O
R,O
As,O
a,O
consistency,O
check,O
.,O
each,O
simulations,O
R0,O
was,O
esti,O
‐,O
mated,O
as,O
follows,O
.,O
to,O
ensure,O
that,O
simulations,O
were,O
properly,O
cali,O
‐,O
brated,O
to,O
their,O
intended,O
values,O
.,O
Note,O
that,O
to,O
vary,O
R0,O
.,O
the,O
pro,O
‐,O
portionality,O
constant,O
in,O
the,O
function,O
that,O
maps,O
viral,O
load,O
to,O
in,O
‐,O
fectiousness,O
need,O
only,O
be,O
adjusted,O
up,O
or,O
down,O
.,O
In,O
a,O
typical,O
SEIR,O
model,TITLE
.,O
this,O
would,O
correspond,O
to,O
changing,O
the,O
infectiousness,O
pa,O
‐,O
rameter,O
which,O
governs,O
the,O
rate,O
at,O
which,O
I,O
‐,O
to,O
‐,O
S,O
contacts,O
cause,O
new,O
infections,CAUSE_OF_DEATH
.,O
For,O
the,O
fully,O
‐,O
mixed,O
.,O
the,O
value,O
of,O
R0,O
was,O
numerical,O
‐,O
ly,O
estimated,O
by,O
running,O
single,O
‐,O
generation,O
simulations,O
in,O
which,O
a,O
50,NUMBER
infected,O
individual,O
were,O
placed,O
in,O
a,O
population,O
of,O
N,O
50,NUMBER
oth,O
‐,O
ers,O
.,O
The,O
number,O
of,O
secondary,O
infections,CAUSE_OF_DEATH
from,O
those,O
initially,O
in,O
‐,O
fected,O
was,O
recorded,O
and,O
used,O
to,O
directly,O
estimate,O
R0,O
.,O
For,O
the,O
agent,O
‐,O
based,O
model,TITLE
.,O
the,O
value,O
of,O
R0,O
depends,O
on,O
the,O
distribution,O
of,O
infected,O
agents,O
due,O
to,O
stratification,O
by,O
age,O
and,O
household,O
.,O
We,O
numerically,O
estimate,O
R0,O
by,O
averaging,O
over,O
the,O
number,O
of,O
secondary,O
infections,CAUSE_OF_DEATH
caused,O
by,O
each,O
agent,O
who,O
was,O
infected,O
in,O
the,O
first,ORDINAL
15,NUMBER
days,DURATION
of,O
the,O
simulation,O
(,O
at,O
which,O
point,O
the,O
population,O
is,O
still,O
more,O
than,O
99.99,PERCENT
%,PERCENT
susceptible,O
),O
.,O
Estimations,O
of,O
R,O
proceeded,O
exact,O
‐,O
ly,O
as,O
estimations,O
of,O
R0,O
for,O
both,O
models,O
.,O
except,O
with,O
interven,O
‐,O
tions,O
applied,O
to,O
the,O
the,O
viral,O
loads,O
and,O
therefore,O
the,O
dynamics,O
.,O
Supplemental,O
Text,O
Adjustments,O
for,O
false,O
negatives,O
and,O
test,O
re,O
‐,O
fusal,O
When,O
an,O
infected,O
individual,O
is,O
not,O
diagnosed,O
.,O
due,O
either,O
refusal,O
to,O
participate,O
in,O
testing,O
or,O
due,O
to,O
a,O
false,O
negative,O
re,O
‐,O
sult,O
unrelated,O
to,O
limit,O
of,O
detectionfor,O
instance,O
due,O
to,O
an,O
im,O
‐,O
properly,O
collected,O
samplethe,O
impact,O
on,O
a,O
surveillance,O
strategys,O
effectiveness,O
can,O
be,O
estimated,O
as,O
follows,O
.,O
Let,O
se,O
be,O
the,O
test,O
sensitivity,O
.,O
in,O
the,O
particular,O
sense,O
of,O
the,O
probability,O
of,O
cor,O
‐,O
rectly,O
diagnosing,O
an,O
individual,O
as,O
positive,O
when,O
that,O
persons,O
vi,O
‐,O
ral,O
load,O
should,O
.,O
in,O
principle,O
.,O
have,O
provided,O
a,O
sufficiently,O
Let,O
f0,O
be,O
the,O
total,O
infectiousness,O
removed,O
with,O
no,O
testing,O
policy,O
.,O
i.e.,O
due,O
to,O
symptom,O
‐,O
driven,O
self,O
isolation,O
.,O
Let,O
ftest,O
be,O
the,O
frac,O
‐,O
tion,O
of,O
total,O
infectiousness,O
removed,O
with,O
a,O
chosen,O
testing,O
poli,O
‐,O
cy,O
.,O
inclusive,O
of,O
symptom,O
‐,O
driven,O
self,O
isolation,O
.,O
assuming,O
that,O
se,O
=,O
1,NUMBER
and,O
r,O
=,O
0,NUMBER
.,O
Note,O
that,O
f0,O
and,O
ftest,O
are,O
the,O
heights,O
of,O
bars,O
in,O
Figs.,O
1C,O
and,O
3C,O
.,O
with,O
f0,O
corresponding,O
to,O
the,O
no,O
test,O
height,O
and,O
ftest,O
corresponding,O
to,O
a,O
testing,O
program,O
.,O
Under,O
these,O
assump,O
‐,O
tions,O
.,O
when,O
se,O
=,O
1,NUMBER
and,O
r,O
=,O
0,NUMBER
.,O
Both,O
f0,O
and,O
ftest,O
can,O
be,O
estimated,O
rapidly,O
via,O
Monte,LOCATION
Carlo,LOCATION
to,O
make,O
this,O
approximation,O
by,O
drawing,O
trajectories,O
and,O
applying,O
a,O
surveillance,O
policy,O
to,O
them1,NUMBER
.,O
In,O
this,O
context,O
.,O
adjusting,O
for,O
false,O
negatives,O
and,O
test,O
refusal,O
is,O
straightforward,O
.,O
When,O
se,O
<,O
1,NUMBER
and,O
/,O
or,O
when,O
r,O
>,O
0,NUMBER
.,O
this,O
approxima,O
‐,O
tion,O
can,O
be,O
modified,O
.,O
The,O
probability,O
that,O
an,O
individual,O
is,O
a,O
non,O
‐,O
refuser,O
and,O
the,O
test,O
does,O
not,O
fail,O
is,O
se,O
(,O
1r,O
),O
.,O
Under,O
the,O
as,O
‐,O
sumption,O
of,O
statistical,O
independence,O
between,O
refusal,O
status,O
.,O
vi,O
‐,O
ral,O
load,O
.,O
and,O
se,O
.,O
the,O
approximation,O
becomes,O
+,O
1,NUMBER
se,O
(,O
1,NUMBER
r,O
),O
R0,O
.,O
R,O
se,O
(,O
1,NUMBER
r,O
),O
which,O
simply,O
expresses,O
a,O
weighted,O
combination,O
of,O
removed,O
infectiousness,O
between,O
a,O
successfully,O
executed,O
test,O
and,O
no,O
test,O
.,O
Intuitively,O
.,O
note,O
that,O
if,O
one,NUMBER
plugs,O
in,O
r,O
=,O
1,NUMBER
(,O
complete,O
refusal,O
),O
or,O
completely,O
failing,O
sensitivity,O
se,O
=,O
0,NUMBER
.,O
then,O
R,O
R0,O
.,O
as,O
expect,O
‐,O
ed,O
.,O
includes,O
this,O
estimate,O
.,O
